Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 7711. Отображено 100.
26-01-2012 дата публикации

Use of a synergistic combination of hypothiocyanite and/or hypohalite ions and lactoferrin for preparing a treatment for cystic fibrosis

Номер: US20120021071A1
Автор: Jean-Paul Perraudin, Philippe Bordeau
Принадлежит: ALAXIA SAS

The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.

Подробнее
Номер записи: 1
16-02-2012 дата публикации

Methods and materials for delivering molecules

Номер: US20120040432A1
Автор: Aimee R. Herdt, Christopher B. Eckman
Принадлежит: Mayo Foundation for Medical Education and Research

This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.

Подробнее
Номер записи: 2
08-03-2012 дата публикации

Methods for preparing stable deoxygenated peg-hemoglobin conjugate solutions comprising an antioxidant

Номер: US20120059153A1
Автор: Ashok S. Malavalli, Kim D. Vandegriff
Принадлежит: Sangart Inc

The present invention is a method for preparing stable HBOC solutions. Specifically, the method comprises the steps of deoxygenating a PEG-Hb conjugate and adding one or more antioxidants during or following the deoxygenating step to form a stabilized PEG-Hb conjugate. The Hb in the PEG-Hb conjugate is not crosslinked and the stabilized PEG-Hb conjugate has a p50 less than that of native SFH from the same animal source when measured under the same conditions. Specifically, the p50 is 6±2 mmHg or less than 10 mmHg.

Подробнее
Номер записи: 3
22-03-2012 дата публикации

Prevention and treatment of blood coagulation-related disases

Номер: US20120073002A1
Автор: Hiroyuki Saito, Kazutaka Yoshihashi, Kunihiro Hattori, Takehisa Kitazawa
Принадлежит: Chugai Pharmaceutical Co Ltd

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Подробнее
Номер записи: 4
12-04-2012 дата публикации

Plants containing a heterologous flavohemoglobin gene and methods of use thereof

Номер: US20120090051A1
Автор: Amarjit Basra, Garrett J. Lee, Linda L. Lutfiyya, Maolong Lu, Mike Edgerton, Wei Wu, Xiaoyun Wu
Принадлежит: Individual

Plant nitrogen use efficiency in corn has been improved by transformation with a flavohemoglobin gene. Plants comprising a flavohemoglobin gene have decreased nitric oxide (NO) levels, increased biomass accumulation under a sufficient nitrogen growth condition, and increased chlorophyll content under a limiting nitrogen growth condition. Additionally, these transformed plants evidence higher levels of yield.

Подробнее
Номер записи: 5
17-05-2012 дата публикации

Lactoferrin-based biomaterials for tissue regeneration and drug delivery

Номер: US20120122767A1
Автор: Lakshmi Sreedharan Nair
Принадлежит: University of Connecticut

The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle.

Подробнее
Номер записи: 6
25-10-2012 дата публикации

Hydrophilic polymer compound having anticoagulation effect

Номер: US20120271010A1
Автор: Hirokazu Sakaguchi, Kazuhiro Tanahashi, Yuka Sakaguchi
Принадлежит: TORAY INDUSTRIES INC

A hydrophilic polymer compound includes a polymer compound which inhibits platelet adhesion, and a compound that inhibits blood coagulation reaction, bound to the polymer compound.

Подробнее
Номер записи: 7
07-02-2013 дата публикации

Method for Removing Endotoxin from Proteins

Номер: US20130035477A1
Автор: Kevin Thomson, Loren S. Ward, Stanley Wroby
Принадлежит: Individual

Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing.

Подробнее
Номер записи: 8
21-03-2013 дата публикации

Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use

Номер: US20130071394A1
Автор: Leffel Elizabeth, Troyer John K.
Принадлежит:

Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning. 1. A composition , comprising an organophosphorus (OP) bioscavenger and a hyaluronan-degrading enzyme.2. The composition of that is formulated for single dosage administration.3. The composition of claim 1 , wherein the organophosphorus bioscavenger is an esterase claim 1 , cholinesterase claim 1 , paraoxonase claim 1 , aryldialkylphosphatase or diisopropylfluorophosphatase.4. The composition of claim 1 , wherein the organophosphorus bioscavenger is selected from among acetylcholinesterase (AChE) claim 1 , butyrylcholinesterase (BChE) claim 1 , prolidase claim 1 , organophosphate acid anhydrolase (OPAA) claim 1 , phosphotriesterase claim 1 , aryldialkylphosphatase claim 1 , organophosphorus hydrolase (OPH) claim 1 , parathion hydrolase claim 1 , diisopropylfluorophosphatase (DFPase) claim 1 , organophosphorus acid anhydrase claim 1 , sarinase and paraoxonase (PON) and an active portion thereof or a variant thereof that exhibits at least 80% OP binding or inactivating activity.5. The composition of claim 1 , wherein the organophosphorus bioscavenger has the sequence of amino acids set forth in any of SEQ ID NOS: 214-256 and 258-301 claim 1 , an active portion thereof or a variant thereof that exhibits at least 80% sequence identity to any of SEQ ID NOS: 214-256 and 258-301.6. The composition of claim 1 , wherein the organophosphorus bioscavenger is butyrylcholinesterase that has the sequence of amino acids set forth in SEQ ID NO:236 claim 1 , or is an active portion thereof or is a variant thereof that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:236.7. The composition of claim 1 , wherein the organophosphorus bioscavenger is modified with a ...

Подробнее
Номер записи: 9
11-04-2013 дата публикации

METHODS FOR THE TREATMENT OF TAY-SACHS DISEASE, SANDHOFF DISEASE, AND GM1-GANGLIOSIDOSIS

Номер: US20130090374A1
Автор: Cachon-Gonzalez Maria Begona, Cox Timothy M., Sena-Esteves Miguel, Seyfried Thomas N.
Принадлежит:

The present disclosure provides methods for the treatment of lysosomal storage disorders using gene replacement therapy. In particular, methods are provided for the treatment of Tay-Sachs disease, Sandhoff Disease, and GM1-gangliosidosis using enzyme replacement therapy. Expression constructs encoding enzymes required for ganglioside metabolism are delivered to the brain of subjects with an enzyme deficiency. Methods are also provided for delaying the onset of, reducing the likelihood of onset of, or reducing the severity of Tay-Sachs disease, Sandhoff Disease, and GM1-gangliosidosis. 1. A method for enhancing β-N-acetylhexosaminidase activity in a subject in need thereof , comprising: (i) the first construct expresses the β-N-acetylhexosaminidase β subunit; and', '(ii) the second construct expresses the β-N-acetylhexosaminidase α subunit;, 'administering to the subject a therapeutically effective amount of a composition comprising a first expression construct and a second expression construct, wherein'}wherein the composition is administered to at least two or more brain areas of the subject, the brain areas selected from the group consisting of thalamus, striatum, deep cerebellar nuclei, and ventral tegmental area.2. The method of claim 1 , wherein the subject is a human predisposed to having claim 1 , suspected of having claim 1 , or diagnosed as having a β-N-acetylhexosaminidase deficiency.3. The method of claim 2 , wherein the β-N-acetylhexosaminidase deficiency comprises a lysosomal storage disorder.4. The method of claim 2 , wherein the β-N-acetylhexosaminidase deficiency comprises Tay-Sachs Disease or Sandhoff Disease.5. The method of claim 2 , wherein the β-N-acetylhexosaminidase deficiency comprises a partial or complete loss of endogenous expression or function of the β-N-acetylhexosaminidase subunit claim 2 , β subunit claim 2 , α subunit claim 2 , or both.6. The method of claim 1 , wherein the expression constructs comprise the adeno-associated virus ( ...

Подробнее
Номер записи: 10
18-04-2013 дата публикации

RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF

Номер: US20130095092A1
Автор: Leavitt Markley C., Quinn Anthony, Xia Zhinan
Принадлежит: Synageva Biopharma Corp.

The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases. 1. A composition comprising an isolated mixture of recombinant human N-acetyl-alpha-D-glucosaminidase (rhNaGlu) comprising the amino acid sequence 24-743 of SEQ ID NO:1 , wherein at least 10% of said rhNaGlu in said mixture comprises at least one glycan structure having mannose-6-phosphate (M6P).2. The composition of claim 1 , wherein said rhNaGlu having M6P is capable of being taken up into a mammalian cell deficient in NaGlu such that internalized rhNaGlu restores at least 50% of normal NaGlu activity observed in a wild-type mammalian cell of the same type.3. The composition of claim 2 , wherein said rhNaGlu contains at least 1 mole of M6P per mole of protein.4. The composition of claim 3 , wherein said rhNaGlu contains about 3 moles of M6P per mole of protein.5. The composition of claim 2 , wherein said mammalian cell deficient in NaGlu is a human cell.6. The composition of claim 2 , wherein said rhNaGlu is effectively delivered to the brain of a mammal having NaGlu deficiency when systemically administered.7. The composition of claim 6 , wherein said rhNaGlu is effectively delivered to the brain of a mammal having NaGlu deficiency when intravenously administered.8. The composition of claim 2 , wherein said rhNaGlu is effectively delivered to the brain of a mammal having NaGlu deficiency when administered intrathecally.9. The composition of claim 2 , wherein ...

Подробнее
Номер записи: 11
18-04-2013 дата публикации

TEMPERATURE-SENSITIVE CARRIER FOR CARRYING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND PREPARATION METHOD THEREOF

Номер: US20130095186A1
Автор: JUNG Young Seok, Na Kun
Принадлежит:

The present invention relates to a temperature-sensitive carrier for carrying a physiologically active substance and a preparation method thereof. Specifically, the temperature-sensitive carrier according to the present invention comprises an amphiphilic biodegradable block copolymer containing polysaccharide or polysaccharide and succinic anhydride as a hydrophilic block and polylactide as a non-ionic block. A hydrophilic polymer-polylactide copolymer according to the present invention forms a stable complex with a physiologically active substance such as protein, polynucleotide and the like in vivo via ionic bonding and temperature-sensitive hydrophobic bonding. Therefore, a copolymer according to the present invention can facilitate in vivo delivery of a physiologically active substance and used as an in vivo drug delivery system. 1. A temperature-sensitive carrier for carrying a physiologically active substance , which comprises a copolymer of (i) a combination of a polysaccharide and succinic anhydride and (ii) polylactide.2. The temperature-sensitive carrier according to claim 1 , wherein said polysaccharide is inherently charged and comprises a non-toxic unit having a molecular weight of at least 5 claim 1 ,000.3. The temperature-sensitive carrier according to claim 2 , wherein said polysaccharide is a hydrophilic pullulan or hyaluronic acid derivative.4. The temperature-sensitive carrier according to claim 1 , wherein (i) a combination of a polysaccharide and succinic anhydride and (ii) polylactide are combined in the weight ratio of 1:0.5 to 1:5.5. The temperature-sensitive carrier according to claim 1 , wherein said carrier is combined with at least one physiologically active substance selected from the group consisting of protein claim 1 , peptide claim 1 , nucleotide and small organic compounds having a hydrophobic or hydrophilic functional group.6. The temperature-sensitive carrier according to claim 5 , wherein said physiologically active substance is ...

Подробнее
Номер записи: 12
25-04-2013 дата публикации

COMPOSITIONS AND METHODS FOR REDUCING MICROBIAL OVERGROWTH IN THE SMALL INTESTINES

Номер: US20130101634A1
Автор: Dawson Hilton Grant, Deaton John, Hersch Theodore
Принадлежит: Deerland Enzymes, Inc.

An antimicrobial composition for reducing bacterial overgrowth in the small intestine is disclosed. The composition comprises a lytic enzyme combined with one or more anti-microbial essential oils, and a probiotic. Unlike broad spectrum antibiotics the disclosed composition does not enter the blood stream, does not destroy all intestinal microflora, and can be used on a continuing basis. 1. An antimicrobial composition , comprising:(a) one or more lytic enzymes;(b) one or more antimicrobial essential oils; and(c) a probiotic.2. The antimicrobial composition of claim 1 , wherein the one or more lytic enzymes are selected from the group consisting of lysozyme claim 1 , lysostaphin claim 1 , zymolase claim 1 , cellulase claim 1 , mutanolysin claim 1 , glycanases claim 1 , proteases claim 1 , mannase claim 1 , and lactoperoxidase.3. The antimicrobial composition of claim 2 , wherein the one or more lytic enzymes comprise egg lysozyme.4. The antimicrobial composition of claim 1 , comprising about 10 mg to about 1000 mg of the one or more lytic enzymes per unit dose.5. The antimicrobial composition of claim 4 , comprising about 75 mg to about 150 mg of the one or more lytic enzymes per unit dose.6. The antimicrobial composition of claim 1 , wherein the one or more antimicrobial essential oils are selected from the group consisting of carvarcol claim 1 , thymol claim 1 , oils of ginger claim 1 , cinnamon claim 1 , mint claim 1 , onion claim 1 , black cumin claim 1 , oregano claim 1 , thyme claim 1 , clove claim 1 , garlic claim 1 , eucalyptus claim 1 , lavender claim 1 , leleshwa claim 1 , lemon claim 1 , lemon myrtle claim 1 , neem claim 1 , cilantro claim 1 , tea tree and peppermint.7. The antimicrobial composition of claim 6 , wherein the one or more antimicrobial essential oils comprise oils of garlic claim 6 , oregano claim 6 , thyme claim 6 , or any combination thereof.8. The antimicrobial composition of claim 1 , wherein the composition comprises about 5 mg to about ...

Подробнее
Номер записи: 13
25-04-2013 дата публикации

COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN

Номер: US20130102521A1
Автор: Vandegriff Kim D., WINSLOW Robert M.
Принадлежит: SANGART, INC.

The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics. 1. A method of treating a human patient in need of treatment , the method comprising administering to the patient a hemoglobin composition comprising polyalkylene oxide (PAO) surface-modified hemoglobin having a Pless than 15 torr as measured at a pH of 7.4 and a temperature of 37° C. and an aqueous diluent ,wherein the patient is suffering from trauma, acute blood loss, ischemia, heart attack, stroke, sepsis, septic shock, anemia, or hypoxia, the patient is having hemodilution as part of a surgical procedure, the patient is having cardioplegia during cardiac surgery, the patient is suffering from cancer and the hemoglobin is used to increase the sensitivity of a tumor to radiation or chemotherapy treatment, or the patient is treated to stimulate hemoglobin synthesis during hematopoiesis; andthe PAO surface-modified hemoglobin is prepared by a process comprising the steps of:thiolating an oxygenated hemoglobin to form thiolated oxygenated hemoglobin; andreacting the thiolated oxygenated hemoglobin with at least one PAO polymer, the PAO polymer comprising a thiol reactive moiety and polyalkylene oxide linked by a linker consisting of alkylene or phenylene.2. The method of wherein the patient is suffering from trauma.3. The method of wherein the trauma is cerebrovascular trauma.4. The method of wherein the patient is suffering from acute blood loss.5. The method of wherein the patient is suffering from ischemia.6. The method of wherein the patient suffered a heart attack.7. The method of wherein the patient suffered a stroke.8. The method of wherein the patient is suffering from sepsis.9. The method of wherein the patient is ...

Подробнее
Номер записи: 14
09-05-2013 дата публикации

Enzyme and Prebiotic Combinations for Enhancing Probiotic Efficacy

Номер: US20130115203A1
Автор: Porubcan Randolph S., Yonak Sonja Lea
Принадлежит:

This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and α-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and β-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts. 1lactobacillus. A formulation for enhancing growth or activity in vivo comprising α-galactosidase and isomalto-oligosaccharide.2the lactobacillusLactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus paracasei, Lactobacillus plantarumLactobacillus rhamnosus.. The formulation of wherein species is or3. The formulation of further including sunflower lecithin or oleic acid.4. The formulation of further including polysorbate 80.5. The formulation of further including pectinase.6. The formulation of further including β-glucanase.7. The formulation of further including milk products including yogurt.8bifidobacterium. A formulation for enhancing growth or activity in vivo comprising β-glucanase and isomalto-oligosaccharide.9bifidobacteriumBifidobacterium lactisBifidobacterium breve.. The formulation of wherein the species is (strain BL-04 or Bi-07) or10. The formulation of further including sunflower lecithin or oleic acid.11. The formulation of further including polysorbate 80.12. The formulation of further including α-galactosidase.13. The formulation of further including pectinase.14. The formulation of further including milk products including yogurt.15lactobacillusbifidobacterium. A formulation for enhancing and growth or activity in vivo comprising α-galactosidase claim 8 , β-glucanase and isomalto-oligosaccharide.16lactobacillusLactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus paracasei, ...

Подробнее
Номер записи: 15
23-05-2013 дата публикации

MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES

Номер: US20130129702A1
Автор: BEHERA ARUNA K., Mohapatra Shyam S.
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence. 126-. (canceled)27. A method of increasing expression of 2′-5′ oligoadenylate synthetase in a mammal , said method comprising administering to the mammal a nucleotide sequence encoding a 2′-5′ oligoadenylate synthetase , or at least one enzymatically active fragment thereof , wherein the nucleotide sequence is expressed in the mammal.28. The method of claim 27 , wherein said nucleotide sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; or an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2 and having 2′-5′ oligoadenylate synthetase activity; or a fragment of SEQ ID NO:2 having 2′-5′ oligoadenylate synthetase activity.29. The method of claim 28 , wherein the nucleotide sequence comprises SEQ ID NO:1 claim 28 , or a fragment of SEQ ID NO:1 that encodes an enzymatically active fragment of SEQ ID NO:2.30. The method of claim 29 , wherein the enzymatically active fragment comprises an enzymatically active subunit of 2′- ...

Подробнее
Номер записи: 16
30-05-2013 дата публикации

COMPOSITIONS AND METHODS FOR TARGETING AND TREATING DISEASES AND INJURIES USING ADENO-ASSOCIATED VIRUS VECTORS

Номер: US20130136729A1
Автор: ANNEX Brian H., French Brent A.
Принадлежит: University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group

The present application discloses compositions and methods useful for targeting and treating injured or diseased muscle, including cardiac and skeletal muscle. Disclosed herein are adenoviral vectors modified to contain enhancers, promoters, and genes to target muscle with high efficiency and to induce tissue specific gene expression of transgenes. 1. A method of preventing or treating an injury , disease , or disorder in cardiac or skeletal muscle , said method comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a recombinant adeno-associated viral (AAV) vector comprising a regulatory element active in muscle cells , wherein said regulatory element comprises at least one promoter element and optionally at least one enhancer element , further wherein said AAV vector comprises at least one gene operably linked to said at least one promoter , or active fragments , modifications , or homologs thereof , thereby preventing or treating an injury , disease , or disorder in cardiac or skeletal muscle.2. The method of claim 1 , wherein at least one promoter element is a tissue specific promoter.3. The method of claim 1 , wherein the AAV is AAVS (SEQ ID NO:11) or AAV9 (SEQ ID NOT).4. The method of claim 1 , wherein the at least one promoter element and the at least one enhancer element are from the same species of animal.5. The method of claim 4 , wherein the species is selected from group consisting of mouse claim 4 , human claim 4 , chicken claim 4 , and rat.6. The method of wherein the vector is AcTnTEcSOD.7. The method of claim 1 , wherein the at least one promoter is selected from the group consisting of a cardiac troponin-T promoter claim 1 , a muscle creatine kinase promoter claim 1 , and a desmin promoter.8. The method of claim 1 , wherein an effective amount of neuraminidase or other desialylation agent is administered to said subject before administration of said AAV vector.9. The method of claim 1 , ...

Подробнее
Номер записи: 17
30-05-2013 дата публикации

Acellular Bioabsorbable Tissue Regeneration Matrices

Номер: US20130136796A1
Автор: Ahlfors Jan-Eric
Принадлежит:

The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue. 178-. (canceled)79. An isolated acellular bioabsorbable tissue regeneration matrix comprising: a proteinaceous core having a protein content of at least 1%; wherein the structure of the acellular bioabsorbable tissue regeneration matrix is characterized by spherical bodies with a diameter of approximately at least 100 nm; and further wherein the acellular bioabsorbable tissue regeneration matrix lacks substantial metabolic activity; and further wherein the acellular bioabsorbable tissue regeneration matrix is capable of initiating more tissue regeneration in a subject with tissue damage , increasing tissue regeneration in a subject with tissue damage , or both.80. The isolated acellular bioabsorbable tissue regeneration matrix of claim 79 , further comprising one or more proteins selected from the group consisting of:transferrin, serum albumin, serum albumin precursor, complement component 3, chains A-D hemoglobin, IgM, IgG1, medullasin inhibitor 2, carbonic anhydrase, CA1 protein, and combinations thereof.81. The isolated acellular bioabsorbable tissue regeneration matrix of claim 79 , wherein the spherical bodies are recognized by CD56 antibodies.82. The acellular bioabsorbable tissue regeneration matrix of claim 79 , wherein the spherical bodies have a diameter of about 1-2 μm.83. The acellular bioabsorbable tissue regeneration matrix of claim 79 , wherein the spherical bodies have a diameter of about 2-4 μm.84. The acellular ...

Подробнее
Номер записи: 18
06-06-2013 дата публикации

Use of transferrin in treatment of beta-thalassemias

Номер: US20130143817A1
Автор: Yelena Z. Ginzburg
Принадлежит: New York Blood Center Inc

Disclosed herein are methods for treating disease, such as diseases of iron overload, including β-thalassemia, comprising administering at least one course of transferrin and thereby reducing the size of the spleen in said patient and reducing the concentration of iron in the tissues and blood.

Подробнее
Номер записи: 19
13-06-2013 дата публикации

Treatment of a disease associated with retinal degenerative disorder

Номер: US20130150304A1
Автор: Emilie Picard, Francine Behar-Cohen, Jean-Claude Jeanny, Yves Courtois
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM

Treatment of a disease associated with retinal degenerative disorder. The present invention relates to human Transferrin or an active fragment thereof for use in the treatment of a disease associated with retinal degenerative disorder.

Подробнее
Номер записи: 20
13-06-2013 дата публикации

MILK-BASED NUTRITIONAL COMPOSITIONS CONTAINING LACTOFERRIN AND USES THEREOF

Номер: US20130150306A1
Автор: Wittke Anja
Принадлежит: MEAD JOHNSON NUTRITION COMPANY

The present disclosure relates to milk-based nutritional compositions comprising lactoferrin and/or a prebiotic component, wherein, when combined, the lactoferrin and prebiotic component may exhibit additive or synergistic beneficial effects on the health and development of a pediatric subject. The disclosure further relates to methods comprising the administration of said milk-based nutritional compositions to pediatric subjects. 1. A method for modulating psychological stress in a pediatric subject , the method comprising administering to the pediatric subject a milk-based nutritional composition comprising lactoferrin from a non-human source.2. The method according to claim 1 , wherein the lactoferrin is bovine lactoferrin.3. The method according to claim 1 , wherein the nutritional composition is an infant formula.4. The method according to claim 1 , wherein the nutritional composition additionally comprises about 3 g/100 kcal to about 7 g/100 kcal of fat source.5. The method according to claim 1 , wherein the nutritional composition additionally comprises about 1 g/100 kcal to about 5 g/100 kcal of a protein source.6. The method according to claim 1 , wherein the lactoferrin is present at a level of about 70 mg/100 kcal to about 220 mg/100 kcal.7. The method according to claim 1 , wherein the nutritional composition further comprises at least one prebiotic.8. The method according to claim 7 , wherein nutritional composition comprises about 0.1 g/100 kcal to about 1 g/100 kcal of the at least one prebiotic.9. The method according to claim 7 , wherein the at least one prebiotic comprises polydextrose.10. The method according to claim 9 , wherein the at least one prebiotic further comprises galactooligosaccharide.11. The method according to claim 9 , wherein polydextrose comprises at least about 20% w/w of the at least one prebiotic.12. A method for modulating plasma corticosterone levels in a pediatric subject claim 9 , the method comprising administering to the ...

Подробнее
Номер записи: 21
20-06-2013 дата публикации

Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury

Номер: US20130156750A1
Автор: Elias Jack A.
Принадлежит: YALE UNIVERSITY

The invention includes methods of treating oxidant-mediated acute lung injury in a subject by administration of a chitinase-like protein molecule, or an activator thereof. The invention also includes methods of assessing the level of a chitinase-like protein molecule in a subject as a marker of the prognosis of a subject suffering from acute lung injury. 1. A method of treating acute lung injury in a subject , said method comprising administering an effective amount of a chitinase-like protein molecule , or activator thereof , to said subject , thereby treating said acute lung injury.2. The method of claim 1 , wherein said chitinase-like protein molecule is YKL-40.3. The method of claim 1 , wherein said acute lung injury is oxidant-mediated acute lung injury.4. The method of claim 1 , wherein said subject is a human.5. A method of preventing acute lung injury in a subject claim 1 , said method comprising administering an effective amount of a chitinase-like protein molecule claim 1 , or activator thereof claim 1 , to said subject claim 1 , thereby preventing said acute lung injury.6. The method of claim 5 , wherein said chitinase-like protein molecule is YKL0-40.7. The method of claim 5 , wherein said acute lung injury is oxidant-mediated acute lung injury.8. The method of claim 5 , wherein said subject is a human.9. A method of determining the severity of acute lung injury in a subject claim 5 , the method comprising:a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury,b. determining in the sample the level of at least one chitinase-like protein molecule,c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard is a measure of the severity of acute lung injury in the subject.10. The ...

Подробнее
Номер записи: 22
20-06-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATING CANCER AND MODULATING STRESS GRANULE FORMATION

Номер: US20130156776A1
Автор: Chang Paul, LEUNG ANTHONY, Sharp Phillip A., Vyas Sejal .
Принадлежит: Massachusetts Institute of Technology

The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors. The invention also provides methods for screening for agents for treating or decreasing the likelihood of developing a stress granule-related disorder or cancer, and methods for determining the propensity for developing a stress granule-related disorder or cancer, as well as compositions and kits containing one or more PARP inhibitors, one or more PARP activators, one or more PARG activators, and one or more ARH3 activators. 1. A method of treating or decreasing the likelihood of developing a stress granule-related disorder in a subject comprising administering to said subject a therapeutically effective amount of one or more poly-ADP-ribose polymerase (PARP) inhibitor(s) , one or more poly-ADP ribose glycolase (PARG) activators , and/or one or more PARP11 activators.2. The method of claim 1 , wherein said one or more PARP inhibitor(s) selectively decrease the expression and/or one or more activities of one or more PARP(s) selected from the group consisting of PARP5a claim 1 , PARP12 claim 1 , PARP13 isoform 1 (PARP13.1) claim 1 , PARP13 isoform 2 (PARP13.2) claim 1 , and PARP15.3. The method of claim 2 , wherein:(a) said decrease in expression is a decrease in the level of one or more nucleic ...

Подробнее
Номер записи: 23
27-06-2013 дата публикации

METHOD FOR TREATING ACIDOSIS IN RUMINANTS

Номер: US20130164275A1
Автор: Lacorte Andrea, Lotto Alessandro
Принадлежит: PHARMACHEM LABORATORIES, INC.

The present invention provides a method for treating acidosis in a ruminant. The method includes administering an effective amount of a naturally derived inhibitor of a carbohydrate degrading enzyme to the ruminant. Such enzymes include amylase and glucosidase. In addition, the carbohydrate degrading enzyme may be endogenous or exogenous to the ruminant. 1. A method for treating acidosis in a ruminant in need thereof comprising administering an effective amount of a naturally derived inhibitor of a carbohydrate degrading enzyme to the ruminant.2. The method according to wherein the inhibitor of a carbohydrate degrading enzyme is derived from a bean.3. The method according to wherein the bean is Phaseolus vulgaris.4. The method according to wherein the carbohydrate-degrading enzyme is endogenous.5. The method according to wherein the enzyme is a pancreatic enzyme.6. The method according to wherein the enzyme is amylase.7. The method according to wherein the enzyme is glucosidase.8. The method according to wherein the carbohydrate degrading enzyme is exogenous.9. The method according to wherein the enzyme is produced by bacteria.10. The method according to wherein the bacteria are carbohydrate-fermenting bacteria in a forestomach of the ruminant.11. The method according to wherein the enzyme is amylase.12. The method according to wherein the enzyme is glucosidase.13. The method according to wherein the acidosis is chronic rumen acidosis.14. The method according to wherein the acidosis is acute rumen acidosis.15. The method according to wherein the acidosis is subacute rumen acidosis.16. The method according to wherein the acidosis is forestomach acidosis.17. The method of wherein the forestomach acidosis is acidosis of the rumen claim 16 , reticulum claim 16 , or omasum of the ruminant.18. The method according to wherein the administration comprises a feed paste claim 1 , pill claim 1 , gel claim 1 , gel cap claim 1 , or tablet.19. The method according to wherein the ...

Подробнее
Номер записи: 24
27-06-2013 дата публикации

AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR

Номер: US20130164276A1
Автор: KADOMATSU Kenji, MATSUYAMA Yukihiro, TAKESHITA Sawako, TANAKA Akiomi
Принадлежит:

An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. 110-. (canceled)11. A method for improving neuropathic pain , comprising administering keratanase II as an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone to a patient suffering from neuropathic pain.12. The method according to claim 11 , wherein said keratanase II is a heat-resistant keratanase II having an excellent stability against heat where the optimum reaction temperature is 50 to 60° C.13. The method according to claim 11 , wherein said keratanase II is administered continuously to a neuropathic site.14. The method according to claim 13 , wherein said keratanase II is administered at the dose of 0.3 milliunit (mU) to 15000 mU per day to an adult human.15. The method according to claim 11 , wherein the neuropathic pain is that arising from spinal cord injury.16. The method according to claim 11 , wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction. The present invention relates to an improving agent for dysfunction due to nerve damage and to an Rho kinase activation inhibitor.In human central nervous system (CNS), it is very difficult to regenerate the neuronal axon which was once injured due to spinal cord injury, cerebrovascular ...

Подробнее
Номер записи: 25
27-06-2013 дата публикации

FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATES

Номер: US20130164365A1
Автор: Fahey Jed, Talalay Antony, Talalay Paul
Принадлежит:

The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided. 1. A formulation comprising:(a) at least one phase II enzyme inducer precursor and(b) at least one activating agent,wherein contact between said precursor and agent is substantially reduced during storage and the formulation is selected from the group consisting of a topical formulation, a pill, a beverage, and a food.2. The topical formulation of claim 1 , wherein said precursor is a glucosinolate.3. The topical formulation of claim 1 , wherein said agent is a myrosinase.4. The topical formulation of claim 1 , wherein said inducer is an isothiocyanate.5. The topical formulation of claim 1 , wherein said precursor and agent are each encapsulated.6. The topical formulation of claim 5 , wherein said precursor and agent are encapsulated in a carrier selected from the group comprising a micelle claim 5 , a liposome claim 5 , and a microsphere.7. The topical formulation of claim 5 , wherein said precursor and agent are encapsulated separately.8. The topical formulation of claim 5 , wherein said precursor and agent are separated by a thin layer.9. The topical formulation of claim 1 , wherein said precursor and agent are not encapsulated.10. The topical formulation of claim 9 , wherein said precursor and agent are placed in separate chambers in a container.11. The topical formulation of claim 9 , wherein said precursor and agent are placed in a thixotropic medium.12. The topical formulation of claim 1 , wherein the formulation is selected from the group consisting of a cream claim 1 , a lotion claim 1 , a gel claim 1 , an ointment claim 1 , a paste claim 1 , and an aerosol spray.13. The topical formulation of claim 1 , wherein the formulation is sterile at least prior to a first use of the formulation.14. The topical formulation of claim 1 , further comprising an antimicrobial ...

Подробнее
Номер записи: 26
04-07-2013 дата публикации

Maturation of gastrointestinal tract

Номер: US20130171121A1
Автор: Björn WESTRÖM, Olena Prykhod'ko, Stefan Pierzynowski
Принадлежит: Anara AB

The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation.

Подробнее
Номер записи: 27
11-07-2013 дата публикации

ANCESTRAL SERINE PROTEASE COAGULATION CASCADE EXERTS A NOVEL FUNCTION IN EARLY IMMUNE DEFENSE

Номер: US20130177547A1
Автор: Dickneite Gerhard, HERWALD Heiko, Loof Torsten, MÖRGELIN Matthias, Theopold Ulrich
Принадлежит:

The present invention relates to blood coagulation factor XIII (FXIII) for treatment and/or prevention of an infection by a microorganism and/or the symptoms associated with said infection, a pharmaceutical composition comprising a pharmaceutically effective amount of said FXIII, a method for the manufacture of a medicament comprising a pharmaceutically effective amount of said FXIII, and a method of treatment comprising administering to a patient in need a pharmaceutically effective amount of said FXIII. 114.-. (canceled)15. A method of treatment and/or prevention of an infection by a microorganism and/or the symptoms associated with said infection comprising:administering to a patient in need thereof a pharmaceutically effective amount of a blood coagulation factor XIII (FXIII).16. The method according to claim 15 , wherein treatment and/or prevention comprises(i) administering FXIII to a patient so that the FXIII concentration in the blood plasma of that patient is increased above the FXIII concentration in the blood plasma of a healthy individual, and/or(ii) administering FXIII to a patient so that an initial concentration of FXIII in the patient's blood plasma is up to 10 fold at its normal level and/or(iii) administering FXIII to a patient who does not suffer from a congenital or acquired FXIII deficiency.17. The method of claim 15 , wherein said FXIII is administered to said patient as part of a pharmaceutical composition.18. The method according to claim 17 , wherein FXIII is administered to a patient systemically or topically to an infected area.19. The method according to claim 17 , wherein FXIII is administered to a patient at a dose of 5 to 1000 international units (IU) per kg body weight.20. The method according to claim 17 , wherein said administering results in dampening systemic dissemination claim 17 , immobilization and/or killing of the microorganism in the body of a patient.21. The method according to claim 15 , wherein the microorganism is ...

Подробнее
Номер записи: 28
11-07-2013 дата публикации

Treatment of Synucleinopathies

Номер: US20130177549A1
Автор: Cheng Seng H., Cullen Valerie, Schlossmacher Michael, Shihabuddin Lamya
Принадлежит: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods. 1. A method of treating a subject with a synucleinopathy , but not a clinically diagnosed lysosomal storage disease , the method comprising administering to a subject any one or more of:an acid-beta-glucocerebrosidase (GBA) polypeptide,a polynucleotide encoding an acid-beta-glucocerebrosidase (GBA) polypeptide,a GBA polypeptide activating polypeptide,a polynucleotide encoding a GBA polypeptide activating agent,a cathepsin D polypeptide,a procathepsin D polypeptide, anda polynucleotide encoding a cathepsin D or procathepsin D polypeptide, in an amount effective to reduce a level of α-synuclein in the subject's central or peripheral nervous system, or both, or in the subject's lysosomal compartment.2. The method of claim 1 , wherein the synucleinopathy is a primary synucleinopathy.3. The method of claim 2 , wherein the synucleinopathy comprises any one or more of: Parkinson's disease (PD); sporadic or heritable dementia with Lewy bodies (DLB); pure autonomic failure (PAF) with α-synuclein deposition; multiple system atrophy (MSA); hereditary neurodegeneration with brain iron accumulation; and incidental Lewy body disease of advanced age.4. The method of claim 1 , wherein the synucleinopathy is a secondary synucleinopathy.5. The method of claim 4 , wherein the synucleinopathy comprises any one or more of: Alzheimer's disease of the Lewy body variant; Down's syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; familial parkinsonism with or without dementia; tau gene and progranulin gene-linked dementia with or without parkinsonism; Creutzfeldt Jakob disease; bovine spongiform encephalopathy; secondary Parkinson disease; parkinsonism resulting from neurotoxin exposure; drug-induced parkinsonism with α-synuclein deposition; sporadic ...

Подробнее
Номер записи: 29
25-07-2013 дата публикации

Hyaluronidase and Method of use Thereof

Номер: US20130189242A1
Автор: Kahojan Eugene G., Uvarkina Tamara P.
Принадлежит:

The present invention provides a tnaluronidase. The hyaiuronidase can be produced by the strain 77. Exemplary characteristics of the hyaluronidase include specific C-terminal or other amino acid sequences, including full-length sequences, and improved physico-chemical and actix itj properties as compared to known h>alνronidase preparatkiiis. Described are also various uses of the hyaiuronidase, including topical administration of the h>aiuronidase to improve skin penetration of a co-administered active substance. 19-. (canceled)10. A method of preventing or reducing scar formation comprising topical administration of a pharmaceutical formulation comprising an isolated hyaluronidase protein comprising an amino acid sequence as set forth in SEQ ID NO:1 , SEQ ID NO:2 or SEQ ID NO:4. and a pharmaceutically acceptable excipient , carrier , diluent , or auxiliary agent to a healing wound in a patient.11. (canceled)12. The method of claim 10 , wherein the wound was caused by burns.13. (canceled)14. A method of preventing or reducing formation of wrinkles comprising topical administration of a pharmaceutical formulation comprising an isolated hyaluronidase protein comprising an amino acid sequence as set fbrth in SEQ ID NO:1 claim 10 , SEQ ID NO:2 or SEQ ID NO:4. and a pharmaceutically acceptable excipient claim 10 , carrier claim 10 , diluent claim 10 , or auxiliary agent t to a skin area susceptible to wrinkle formation in a subject.1516-. (canceled)17. The method of claim 10 , wherein the scar is a keloid scar.1822-. (canceled)22. A method of improving the tissue penetration of a drug comprising administering the drug together with a pharmaceutical formulation comprising an isolated hyaluronidase protein comprising an amino acid sequence as set forth in SEQ ID NO:1 claim 10 , SEQ ID NO:2 or SEQ ID NO:4. and a pharmaceutically acceptable excipient claim 10 , carrier claim 10 , diluent claim 10 , or auxiliary agent to a subject.23. The method of claim 22 , wherein the ...

Подробнее
Номер записи: 30
01-08-2013 дата публикации

TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II

Номер: US20130195834A1
Автор: Chen Yuan-Tsong
Принадлежит: Duke University

Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. 1. A method of treating glycogen storage disease type II in an individual , comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase at a regular interval.2. The method of claim 1 , wherein the glycogen storage disease type II is infantile glycogen storage disease type II.3. The method of claim 1 , wherein the glycogen storage disease type II is juvenile glycogen storage disease type II.4. The method of claim 1 , wherein the glycogen storage disease type II is adult-onset glycogen storage disease type II.5. The method of claim 1 , wherein the therapeutically effective amount of human acid α-glucosidase is less than about 15 mg of acid α-glucosidase per kilogram of body weight of the individual.6. The method of claim 5 , wherein the therapeutically effective amount of human acid α-glucosidase is about 1-10 mg of acid α-glucosidase per kilogram of body weight of the individual.7. The method of claim 5 , wherein the therapeutically effective amount of human acid α-glucosidase is about 5 mg of acid α-glucosidase per kilogram of body weight of the individual.8. The method of claim 1 , wherein the human acid α-glucosidase is recombinant human acid α-glucosidase.9. The method of claim 1 , wherein the human acid α-glucosidase is a precursor of recombinant human acid α-glucosidase.10. The method of claim 9 , wherein the recombinant human acid α-glucosidase is produced in Chinese hamster ovary cells.11. The method of claim 1 , wherein the regular interval is monthly.12. The method of claim 1 , wherein the regular interval is bimonthly.13. The method of claim 1 , wherein the regular interval is weekly.14. The method of claim 1 , wherein the regular interval is twice weekly.15. The method of claim 1 , wherein the regular interval is daily.16. The ...

Подробнее
Номер записи: 31
01-08-2013 дата публикации

METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY

Номер: US20130195837A1
Автор: Borow Kenneth, Wilson D. Travis
Принадлежит:

This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). 1. A method for treating a vessel occlusion injury in a mammalian subject , the method comprising:{'sub': '2', '(a) administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NHor a pharmaceutically acceptable salt thereof; and'}(b) performing a revascularization procedure on the subject.2. The method of claim 1 , wherein the subject is administered the peptide prior to the revascularization procedure.3. The method of claim 1 , wherein the subject is administered the peptide after the revascularization procedure.4. The method of claim 1 , wherein the subject is administered the peptide during and after the revascularization procedure.5. The method of claim 1 , wherein the subject is administered the peptide continuously before claim 1 , during claim 1 , and after the revascularization procedure.6. The method of claim 5 , wherein the subject is administered the peptide for at least 3 hours after the revascularization procedure.7. The method of claim 5 , wherein the subject is administered the peptide starting at about 1 hour before the revascularization procedure.8. The method of claim 5 , wherein the subject is administered the peptide starting at about 30 minutes before the revascularization procedure.9. The method of claim 1 , wherein the subject is suffering from a myocardial infarction.10. The method of claim 1 , wherein the subject is suffering from a ST elevation myocardial infarction or a non-ST elevation myocardial infarction.11. The method of claim 1 , wherein the subject is in need of angioplasty.12. The method of claim 1 , wherein the revascularization procedure is selected from the group consisting of: balloon ...

Подробнее
Номер записи: 32
08-08-2013 дата публикации

Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

Номер: US20130202583A1
Автор: HUANG Lei, Jiang Ping, Shepard H. Michael
Принадлежит:

Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided. 1. A method for selecting a subject for treatment of a tumor with an anti-hyaluronan agent , comprising:a) contacting a tissue or body fluid sample from a subject with a tumor or cancer with a hyaluronan binding protein (HABP) molecule, wherein the HABP has not been prepared from or isolated from animal cartilage;b) detecting binding of the hyaluronan binding protein to the sample, thereby determining the amount of hyaluronan in the sample, wherein if the amount of hyaluronan in the sample is at or above a predetermined threshold level, selecting the subject for treatment with an anti-hyaluronan agent; andc) treating the selected subject with an anti-hyaluronan agent.2. The method of claim 1 , wherein the predetermined threshold level is high HA.3. The method of claim 1 , wherein:the predetermined threshold level is at least or above 0.025 μg HA/ml of sample; or{'sup': +2', '+3, 'the predetermined threshold is an HA score of at least +2 (HA) or at least +3 (HA); or'}the predetermined threshold level is at least a percent HA positive pixels in tumor (cells and stroma) to total stain in tumor tissue of at least 10%, 10% to 25% or greater than 25%.4. The method of claim 1 , wherein:the HABP molecule comprises a link module; orthe HABP molecule comprises a G1 domain of a type C hyaluronan binding protein.5. The method of claim 4 , wherein the link module or G1 domain is the only HABP portion of the molecule.6. The method of claim 4 , wherein the HABP molecule comprises a link module and the link module is selected from among ...

Подробнее
Номер записи: 33
08-08-2013 дата публикации

ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma

Номер: US20130202594A1
Автор: BHATT Rupal S., Kumar Ravindra, Mier James W., Pearsall Robert, SHERMAN Matthew, Solban Nicolas
Принадлежит:

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo. 1. A method of treating renal cell carcinoma (RCC) in a mammal , comprising administering to a mammal that has RCC an effective amount of a receptor tyrosine kinase inhibitor (RTKI) and an agent selected from:(a) an ALK1 polypeptide comprising a ligand binding portion of the extracellular domain of ALK1;(b) an anti body that hinds to the extracellular domain of human ALK1;(c) an antibody that binds to human BMP9; and(d) an antibody that binds to human BMP10.2. The method of claim 1 , wherein the ALK1 polypeptide comprises a polypeptide having claim 1 , an amino acid sequence that is at least 90% identical to the sequence of amino acids 22-118 of SEQ ID NO: 1 claim 1 , and wherein the ALK1 polypeptide binds to an ALK1 ligand selected from GDF5 claim 1 , GDF6 claim 1 , GDF7 claim 1 , BMP9 and BMP10.3. The method of claim 2 , wherein the ALK1 polypeptide comprises a polypeptide having an amino acid sequence that is at least 90% identical to the sequence of amino acids 22-120 of SEQ ID NO:1.4. The method of claim 2 , wherein the ALK1 polypeptide further comprises a constant domain of an immunoglobulin.5. The method of claim 2 , wherein the ALK1 polypeptide further comprises an Fc portion of an immunoglobulin.6. The method of claim 5 , wherein the Fc portion is an Fc portion of a human IgG1.7. The method of claim 1 , wherein the ALK1 polypeptide comprises an amino acid sequence that is at least 90% identical to the sequence of SEQ ID ...

Подробнее
Номер записи: 34
08-08-2013 дата публикации

Methods and means for diagnosing spondylarthritis using autoantibody markers

Номер: US20130203088A1
Автор: Niklas Thomas BAERLECKEN, Torsten Witte
Принадлежит: MEDIZINISCHE HOCHSCHULE HANNOVER

The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis.

Подробнее
Номер записи: 35
15-08-2013 дата публикации

BIODEGRADABLE PHASE SEPARATED SEGMENTED MULTI BLOCK CO-POLYMERS AND RELEASE OF BIOLOGICALLY ACTIVE POLYPEPTIDES

Номер: US20130209568A1
Автор: FLIPSEN Theodorus Adrianus Cornelius, HIEMSTRA Christine, STEENDAM Rob, ZUIDEMA Johan
Принадлежит: InnoCore Technologies B.V.

The invention is directed to biodegradable, thermoplastic, phase separated segmented multi-block copolymers. The copolymers of the present invention find use in various biomedical applications as well as in pharmaceutical applications. Provided is a composition for the controlled release of at least one biologically active polypeptide to a host, comprising the at least one biologically active polypeptide encapsulated in a matrix comprising at least one phase separated, thermoplastic multi-block copolymer, the copolymer being characterized in that (i) it comprises at least two hydrolysable segments chosen from prepolymer (A) and prepolymer (B), prepolymer (A) having a Tg lower than 37° C. and prepolymer (B) having a Tm of 40° C.-100° C. under physiological conditions; (ii) the segments being linked by a multifunctional chain-extender; (iii) the segments are randomly distributed over the polymer chain; and (iv) prepolymer (A) contains a segment that is derived from a water soluble polymer. 1. A composition for the controlled release of at least one biologically active polypeptide to a host , comprising the at least one biologically active polypeptide encapsulated in a matrix comprising at least one phase separated , thermoplastic multi-block copolymer , the copolymer being characterized in that:(v) it comprises at least two hydrolysable segments chosen from prepolymer (A) and prepolymer (B), prepolymer (A) having a Tg lower than 37° C. and prepolymer (B) having a Tm of 40° C.-100° C. under physiological conditions;(vi) the segments being linked by a multifunctional chain-extender;(vii) the segments are randomly distributed over the polymer chain;(viii) prepolymer (A) contains a segment that is derived from a water soluble polymer.2. Composition according to claim 1 , wherein said chain-extender is a difunctional aliphatic chain-extender claim 1 , preferably a diiosocyanate.3. Composition according to claim 1 , wherein prepolymer (A) comprises ester and/or carbonate ...

Подробнее
Номер записи: 36
15-08-2013 дата публикации

METHODS OF INHIBITING AND TREATING BACTERIAL BIOFILMS BY METAL CHELATORS

Номер: US20130210708A1
Автор: Greenberg Everett P., SINGH Pradeep K., Welsh Michael J.
Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. 1. A method of inhibiting biofilm formation by bacteria comprising contacting said bacteria with an effective amount of a metal chelator , to thereby inhibit biofilm formation by said bacteria.210-. (canceled)11. A method of stimulating surface motility in bacteria comprising contacting said bacteria with a metal chelator.1221-. (canceled)22. A method of inhibiting biofilm development by bacteria in a subject comprising administering to said subject an effective amount of a metal chelator , thereby inhibiting biofilm development by said bacteria in said subject.2332-. (canceled)33. A method of treating a subject suffering from a bacterial infection comprising administering to said subject a composition comprising a therapeutically effective amount of a metal chelator , thereby treating the subject suffering from a bacterial infection.3455-. (canceled)56. A pharmaceutical composition comprising a therapeutically effective amount of a metal chelator and a pharmaceutically acceptable carrier.5768-. (canceled)69. A method of inhibiting biofilm formation on a device comprising , contacting said device with a compound comprising an effective amount of a metal chelator , thereby inhibiting the formation of biofilm on said device.7076-. (canceled)77. A kit for treating a bacterial infection comprising a metal chelator and directions for use.78101-. (canceled) This application is a continuation of U.S. application Ser. No. 12/288,449, filed on Oct. 20, 2008, which is a continuation of U.S. Pat. No. 7,446,089B, issued on Nov. 4, 2008, which is a continuation of PCT/US03/12128, filed on Apr. 18, 2003, which claims the benefit of U.S. provisional application Ser. ...

Подробнее
Номер записи: 37
22-08-2013 дата публикации

STANDARDIZED BEE VENOM PREPARATION

Номер: US20130216517A1
Автор: Kim Christopher M.
Принадлежит:

Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy. 1. A standardized bee venom preparation comprising a liquid carrier , from about 0.1 milligram (mg) to about 1.0 mg of pure melittin , and from about 400 microgram (mcg) to about 4 ,500 mcg of total protein per milliliter (mL) of said standardized bee venom preparation , wherein said standardized bee venom preparation exhibits 40 to 100 honey bee hyaluronidase units per mL (HHU/mL) of hyaluronidase activity when diluted to 100 mcg/mL and is capable of inhibiting gelatin induced aggregation of erythoricytes of 3-5 millimeter per hour (mm/H).2. The standardized bee venom preparation of claim 1 , wherein the liquid carrier is sterile deoinized water or physiological saline solution.3. The standardized bee venom preparation of claim 1 , further comprising an excipient selected from the group consisting of a viscosity modifier claim 1 , preservative claim 1 , additive claim 1 , sodium chloride claim 1 , saccharide claim 1 , benzyl alcohol claim 1 , methyl paraban and mixtures thereof.4. The standardized bee venom preparation of claim 1 , further comprising an anesthetic.5. The standardized bee venom preparation of claim 4 , wherein said anesthetic is selected from the group consisting of ambucaine claim 4 , amolanone claim 4 , amylocalne hydrochloride claim 4 , benoxinate claim 4 , benzocaine claim 4 , betoxycaine claim 4 , biphenamine claim 4 , bupivacaine claim 4 , butacaine claim 4 , butamben claim 4 , butanilicaine claim 4 , butethamine claim 4 , butoxycaine claim 4 , carticaine claim 4 , chloroprocaine hydrochloride claim 4 , cocaethylene claim 4 , cocaine claim 4 , cyclomethycaine claim 4 , dibucaine hydrochloride claim 4 , dimethisoquin claim 4 , dimethocaine claim 4 , diperodon hydrochloride claim 4 , ...

Подробнее
Номер записи: 38
29-08-2013 дата публикации

AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE

Номер: US20130224171A1
Автор: SILCOFF Elliad Ronen, WYROBNIK Daniel Henry, Wyrobnik Isaac Harry
Принадлежит: PRO NATURA GESELLSCHAFT FUR GESUNDE ERNAHRUNG MBH

5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed. 1139-. (canceled)140. A method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism , the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of 5-D-fructose dehydrogenase.141. A method according to wherein said condition is fructose intolerance that is selected from the group consisting of (a) hereditary fructose intolerance claim 140 , (b) intestinal fructose intolerance claim 140 , (c) fructose intolerance that is due to a lack of fructose 1 claim 140 ,6-diphosphatase and (d) combinations thereof.142. (canceled)143. A method according to claim 140 , wherein said 5-D-fructose dehydrogenase is administered with a second enzyme which cleaves fructose from a sugar which is more complex than fructose.144. A method according to wherein said second enzyme is selected from the group consisting of invertase claim 143 , maltase and combinations thereof.145. A method according to claim 140 , wherein said administration comprises oral administration.146. A mammalian ingestible composition of matter which is adapted for oral administration selected from a pharmaceutical composition and a dietary supplement claim 140 , said composition of matter being in unit dosage form claim 140 , said composition of matter comprising 5-D-fructose dehydrogenase and a carrier or excipient that is acceptable for use in pharmaceutical compositions or foodstuffs.147148-. (canceled)149. A composition of matter according to which is in a form selected from (a) the group consisting of a tablet claim 146 , capsule claim 146 , gel cap claim 146 , pellet and dragee claim 146 , (b) powder or (c) liquid form as solution claim 146 , drops claim 146 , suspension or gel.150152-. (canceled ...

Подробнее
Номер записи: 39
29-08-2013 дата публикации

METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS

Номер: US20130224172A1
Автор: Fallon James J., Fallon Joan M., HEIL Matthew F., NANUS Kenneth, SZIGETHY James
Принадлежит: CUREMARK, LLC

Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. 1. A method of treating a subject with one or more symptoms of an ASD , comprising:administering to the subject a pharmaceutical composition comprising one or more excipients and a therapeutic composition, wherein the therapeutic composition comprises protease, amylase and/or lipase,wherein the subject exhibits improvement in one or more symptoms of an ASD comprising:(a) protein intake, fat intake, carbohydrate intake, vitamin intake, diarrhea, constipation, seizures, and/or bone fragility; and/or(b) hyperactivity, irritability, agitation, obsessive compulsive behavior, eye contact, speech, lethargy, hypersensitivity, stereotypy, toilet training, non-compliance, inattention, aggression, impulsivity, conduct disorder, or oppositional defiance and/or social withdrawal and wherein the subject has a greater improvement in the one or more symptoms of an ASD after administration of the pharmaceutical composition than a subject a subject with one or more symptoms of an ASD administered a placebo.23-. (canceled)4. The method of claim 1 , wherein the subject exhibits a 10% or greater improvement in one or more symptoms of an ASD after administration of the pharmaceutical composition in comparison to before the subject was administered the pharmaceutical composition.58-. (canceled)9. The method of claim 1 , wherein the greater the amount of daily protein claim 1 , fat claim 1 , carbohydrate and/or vitamin intake (by weight) consumed by the subject after administration of ...

Подробнее
Номер записи: 40
29-08-2013 дата публикации

Recombinant therapeutic glycine n-acyltransferase

Номер: US20130224175A1
Автор: Alberdina Aike Van Dijk, Christoffel Petrus Stephanus Badenhorst, Lodewyk Jacobus Mienie, Rencia Van Der Sluis
Принадлежит: NORTH WEST UNIVERSITY

This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 2.1.3.13)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression piasmid; transforming the host with the expression piasmid to form an expression system; expressing the GLYAT gene in the expression system; and separating the expressed GLYAT from the expression system.

Подробнее
Номер записи: 41
29-08-2013 дата публикации

METHOD OF RESTORING THE INCRETIN EFFECT

Номер: US20130224176A1
Автор: Clemens Anton H.
Принадлежит: NEURENDO PHARMA, LLC

The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof. 137-. (canceled)38. A method of treating type 2 diabetes mellitus comprising administering to a subject a therapeutically effective amount of a selective .kappa.-receptor antagonist , or a pharmaceutically acceptable derivative thereof.39. The method of claim 38 , wherein the selective .kappa.-receptor antagonist is GNTI.40. The method of claim 38 , wherein the selective .kappa.-receptor antagonist is administered weekly or daily.41. The method of claim 40 , wherein the selective .kappa.-receptor antagonist is administered weekly in an amount from about 30 ng to about 300 ng per kg of body weight weekly.42. The method of claim 40 , wherein the selective .kappa.-receptor antagonist is administered daily in an amount from about 8 ng to about 80 ng per kg of body weight daily.43. The method of claim 38 , wherein the selective .kappa.-receptor antagonist is administered sublingually claim 38 , orally claim 38 , enterally claim 38 , parenterally claim 38 , topically claim 38 , systemically or injected intravascularly claim 38 , subcutaneously claim 38 , peritoneally.44. The method of claim 38 , further comprising co-administration of an effective amount of an insulinogenic agent.45. The method of claim 44 , wherein the insulinogenic agent is an extended release composition.46. The method of claim 38 , wherein a .mu.-agonist is not co-administered.4777-. (canceled) This ...

Подробнее
Номер записи: 42
29-08-2013 дата публикации

METHOD OF REGULATING FERTILIZING ABILITY USING CYCLIC ADP-RIBOSE AND CD38

Номер: US20130224177A1
Автор: Kim Byung-Ju, Kim Uh-Hyun, Park Kwang-Hyun
Принадлежит: Industrial Cooperation Foundation Chonbuk National University

The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization. 1. (canceled)2. A pharmaceutical composition for promoting fertilization comprising CD38.34-. (canceled)5. A method of promoting fertilization by increasing the motility of sperm , the method comprising a step of promoting the synthesis of cyclic ADP-ribose.6. The method of claim 5 , wherein the cyclic ADP-ribose is synthesized in prostasome-bound sperm.7. The method of claim 5 , wherein the method further comprises a step of treating the sperm with progesterone.8. The method of claim 7 , wherein the treatment with the progesterone promotes intracellular calcium release to induce a continuous increase in calcium.9. A pharmaceutical composition for contraception comprising an antagonist of cyclic ADP-ribose.10. The pharmaceutical composition of claim 9 , wherein the antagonist is 8-Br-cADPR or 8-amino-cADPR.11. The pharmaceutical composition of claim 9 , wherein the cyclic ADP-ribose is synthesized in CD38 contained in prostasome.12. The pharmaceutical composition of claim 9 , wherein the antagonist inhibits a pattern of a continuous increase in calcium by progesterone.13. A method for inhibiting fertilization comprising inhibiting cyclic ADP-ribose.14. The method of claim 13 , wherein the inhibition is performed by treatment with an antagonist of the cyclic ADP-ribose.15. The pharmaceutical composition of claim 10 , wherein the antagonist inhibits a pattern of a continuous increase in calcium by progesterone. 1. Field of the InventionThe present invention ...

Подробнее
Номер записи: 43
29-08-2013 дата публикации

Compositions and Methods for Treating Neurological Disorders

Номер: US20130224223A1
Автор: Li Xiaoming, Mei Lin, Woo Ran-Sook, Xiong Wen-Cheng
Принадлежит: GEORGIA REGENTS UNIVERSITY

Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject. 1. A pharmaceutical composition comprising an ErbB4 antagonist ligand in an amount effective to decrease GABAergic transmission in a subject.2. The pharmaceutical composition of wherein the ErbB4 antagonist ligand comprises soluble ErbB4.3. The pharmaceutical composition of wherein the ErbB4 antagonist ligand promotes a stimulatory response in host by reducing or inhibiting GABAergic transmission.4. The pharmaceutical composition of claim 1 , wherein the ErbB4 antagonist ligand comprises a small molecule ligand.5. The pharmaceutical composition of claim 4 , wherein the small molecule ligand inhibits the interaction between NRG1 and ErbB4.6. The pharmaceutical composition of further comprising a second therapeutic agent.7. The pharmaceutical composition of wherein the second therapeutic agent is selected from the group consisting of diazepam claim 6 , methamphetamine claim 6 , amphetamine and dextroamphetamine claim 6 , gabapentin claim 6 , potassium chloride claim 6 , methylphenidate claim 6 , clonazepam claim 6 , modafinil claim 6 , lamotrigine claim 6 , aripiprazole claim 6 ...

Подробнее
Номер записи: 44
29-08-2013 дата публикации

Oral Lactoferrin in the Treatment of Severe Sepsis

Номер: US20130225477A1
Автор: Petrak Karel, Varadhachary Atul
Принадлежит: AGENNIX AG

The present invention relates to lactoferrin for use in the treatment of severe sepsis. In particular, the present invention relates to methods of effectively treating sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin (LF). More particularly, the present invention relates to methods of treating prophylactically or therapeutically sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin to patients with an APACHE II score ≦25, in particular <25. 110.-. (canceled)11. A method for treating sepsis in a patient comprising administering to the patient having severe sepsis a composition comprising lactoferrin in a pharmaceutically acceptable carrier.12. The method of claim 11 , wherein the composition is administered orally.13. The method of claim 11 , wherein the patient has a baseline APACHE II score of ≦25.14. The method of claim 11 , wherein the patient has a baseline APACHE II score of <21.15. The method of claim 11 , wherein the severe sepsis comprises at least one organ dysfunction.16. The method of claim 11 , wherein the severe sepsis comprises no more than one organ dysfunction.17. The method of claim 11 , wherein the patient has unimpaired cardiovascular function.18. The method of claim 11 , wherein the lactoferrin is human lactoferrin.19. The method of claim 11 , wherein the patient is less than 18 years old.20. The method of claim 11 , wherein the lactoferrin in the composition is administered in a dosage amount of 1.5 mg to 100 g every 8 hours.21. The method of claim 11 , wherein the lactoferrin in the composition is administered in a dosage amount of 1.0 mg to 5 g every 8 hours.22. The method of claim 12 , wherein the lactoferrin in the composition is administered orally and the lactoferrin in the composition is in a dosage amount of 1.5 mg to 100 g every 8 hours.23. The method of claim 12 , wherein the lactoferrin in the composition is administered orally and the lactoferrin in the ...

Подробнее
Номер записи: 45
12-09-2013 дата публикации

METHODS OF TREATING AND PREVENTING THROMBOTIC DISEASES USING ASK1 INHIBITORS

Номер: US20130236441A1
Автор: Naik Meghna U., Naik Ulhas P.
Принадлежит: University of Delaware

A method of treating or preventing a thrombotic disease in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein. A method of identifying an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein useful for treating or preventing a thrombotic disease, comprising (a) contacting a candidate agent with a test sample comprising the ASK1 protein, and (b) comparing the ASK1 protein activity in the test sample with the ASK1 protein activity in a control sample that has not been contacted with the candidate agent, whereby a decrease in the ASK1 protein activity in the test sample compared with the control sample indicates that the candidate agent is an ASK1 inhibitor. 1. A method of treating or preventing a thrombotic disease in a subject in need thereof , comprising administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein.2. The method of claim 1 , wherein the thrombotic disease is selected from the group consisting of venous thrombosis claim 1 , arterial thrombosis claim 1 , atherosclerosis claim 1 , arthritis claim 1 , coagulopathy claim 1 , deep venous thrombosis (DVT) claim 1 , disseminated intravascular coagulopathy (DIC) claim 1 , pulmonary thromboembolism claim 1 , Budd-Chiari syndrome claim 1 , Paget-Schroetter diseases claim 1 , stroke and myocardial infraction.3. The method of claim 1 , wherein the ASK1 protein is obtained from activated platelets.4. The method of claim 3 , wherein the activated platelets are obtained from a subject who has suffered from the thrombotic disease.5. The method of claim 1 , wherein the ASK1 protein comprises an amino acid sequence of SEQ ID NO: 1 claim 1 , and wherein the ASK1 inhibitor is capable of attenuating phosphorylation of threonine 838 (T838) in SEQ ID NO: 1.6. The ...

Подробнее
Номер записи: 46
12-09-2013 дата публикации

METHOD OF TREATMENT

Номер: US20130236508A1
Автор: HOBMAN Peter, Nicholson Geoff, ROWNEY Michelle, Sanders Kerrie
Принадлежит: MURRAY GOULBURN CO-OPERATIVE CO. LIMITED

The method relates to a method of treating proteinuria comprising administering lactoferrin. 1. A method of treating proteinuria comprising administering to a subject in need thereof a therapeutically effective amount of lactoferrin.2. The method of claim 1 , wherein the proteinuria is albuminuria or microalbuminuria.3. The method of claim 1 , wherein the proteinuria is diagnosed using a urinary albumin/creatinine ratio (ACR).4. The method of claim 3 , wherein the ACR of the subject when the proteinuria is diagnosed is greater than or equal to about 2 mg/mmol.5. The method of claim 1 , wherein the proteinuria is diagnosed using a blood urea nitrogen (BUN)/creatinine ratio or a urea/creatinine ratio.6. The method of claim 1 , further comprising administering to the subject an ACE inhibitor or an ARB.7. The method of claim 1 , wherein the lactoferrin is administered orally.8. The method of claim 7 , wherein the lactoferrin is administered orally as a food claim 7 , a drink claim 7 , a supplement claim 7 , a nutraceutical claim 7 , or a medicament.9. The method of claim 7 , wherein the lactoferrin that is administered orally is encapsulated claim 7 , microencapsulated or nanoencapsulated. The invention relates to methods of treating proteinuria or diseases associated with proteinuria.All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.Urinary protein loss (proteinuria) affects some 100 million people worldwide and is a feature of kidney dysfunction, including inflammation, of glomerular origin. Proteinuria itself is a risk factor for both renal and extra-renal diseases.Proteinuria usually reflects an increase in glomerular permeability for normally non-filtered ...

Подробнее
Номер записи: 47
19-09-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS

Номер: US20130243743A1
Автор: Kumar Ravindra, Pearsall Robert Scott, Seehra Jasbir, Suragani Naga Venkata Sai Rajasekhar
Принадлежит: Acceleron Pharma, Inc.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. 1. A method for treating ineffective erythropoiesis in a patient , the method comprising administering to a patient in need thereof a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1 , and wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1.2. The method of claim 1 , wherein the patient has a disorder selected from the group: splenomegaly claim 1 , iron overload claim 1 , erythroblast-induced bone pathology and bone marrow hypercellularity.3. The method of claim 1 , wherein the patient has a disorder selected from the group: thalassemia claim 1 , sideroblastic anemia and dyserythropoietic anemia.4. The method of claim 1 , wherein the patient has tissue iron overload.5. The method of claim 1 , wherein the patient has extramedullary erythropoiesis or splenomegaly.6. The method of claim 1 , wherein the patient has erythroblast-induced bone pathology.7. The method of claim 1 , wherein the patient has undesirably high levels of endogenous erythropoietin.8. The method of claim 1 , wherein the patient has a thalassemia syndrome.9. The method of claim 8 , wherein the patient has a β-thalassemia syndrome.10. The method of claim 9 , wherein the patient has β-thalassemia intermedia.11. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1.12. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 98% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1.13. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is identical to the ...

Подробнее
Номер записи: 48
19-09-2013 дата публикации

Methods and materials for treatment of pompe's disease

Номер: US20130243746A1
Автор: Gwenda Noëlla Pynaert, Jan Robert Ludo Stout, Kathleen Camilla Telesphore Alida Maria Piens, Wouter Vervecken
Принадлежит: Oxyrane UK Ltd

This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.

Подробнее
Номер записи: 49
26-09-2013 дата публикации

Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

Номер: US20130251786A1
Автор: Bookbinder Louis Howard, FROST Gregory Ian, Li Xiaoming, Ramprasad Mysore, Shepard Harold Michael, Thompson Curtis
Принадлежит:

Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia. 1. A multivesicular liposome having a hyaluronan-degrading enzyme encapsulated therein , comprising:a) a neutral lipid;an amphipathic lipid; anda hyaluronan-degrading enzyme, wherein the concentration of the hyaluronan-degrading enzyme is between or about between 0.1 mg/mL to 1 mg/mL; orb) a neutral lipid;an amphipathic lipid;a hyaluronan-degrading enzyme; andhyaluronic acid in an amount sufficient to increase the encapsulation and enzymatic activity of the hyaluronan-degrading enzyme.2. The multivesicular liposome of claim 1 , wherein the multivesicular liposome is of a) and further comprises hyaluronic acid in an amount sufficient to increase the encapsulation and enzymatic activity of the hyaluronan-degrading enzyme.3. The multivesicular liposome of claim 1 , wherein the hyaluronic acid maintains the total activity of the enzyme of at least 40 claim 1 ,000 U/mg.4. The multivesicular liposome of claim 2 , wherein the hyaluronic acid maintains the total activity of the enzyme of at least 40 claim 2 ,000 U/mg.5. The multivesicular liposome of claim 1 , wherein the hyaluronan-degrading enzyme is a hyaluronidase claim 1 , a chondroitinase or a lyase.6. The multivesicular liposome of claim 5 , wherein the hyaluronan-degrading enzyme is a hyaluronidase that is a PH20 hyaluronidase.7. The multivesicular liposome of claim 6 , wherein the PH20 is soluble or is a form that is secreted when expressed.8. The multivesicular ...

Подробнее
Номер записи: 50
26-09-2013 дата публикации

Process for preparing orally administered dabigatran formulations

Номер: US20130251810A1
Автор: Sabine Landerer, Thomas Friedl
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to an improved process for preparing a new medicament formulation of the active substance dabigatran etexilate of formula I in the form of the methanesulphonic acid salt thereof, and this new medicament formulation as such.

Подробнее
Номер записи: 51
03-10-2013 дата публикации

LYSOZYME GEL FORMULATIONS

Номер: US20130259852A1
Автор: Di Schiena Michele Giuseppe, FERRARI Stefano, RONGEN ROELOF
Принадлежит:

The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use. 1. A composition comprising gelled lysozyme , water and a solvent , wherein the gelled lysozyme retains at least one activity.2. The composition according to claim 1 , wherein the solvent is an organic solvent.3. The composition according to claim 2 , wherein the organic solvent is miscible with water but one in which lysozyme does not substantially dissolve.4. The composition according to claim 2 , wherein the organic solvent is an alcohol.5. The composition according to claim 4 , in which the alcohol is selected from the group consisting of ethanol claim 4 , methanol claim 4 , propanol claim 4 , butanol claim 4 , isopropyl alcohol claim 4 , isobutyl alcohol claim 4 , isoamyl alcohol claim 4 , isopropylalcohol claim 4 , benzylalcohol claim 4 , and polyvinylalcohol.6. The composition according to claim 2 , in which the organic solvent is selected from the group consisting of dioxane claim 2 , mercaptoethanol and acetonitrile.7. The composition according to claim 1 , in which the lysozyme is a free base.8. The composition according to claim 1 , in which the lysozyme is a salt.9. The composition according to claim 8 , in which the lysozyme is an organic salt.10. The composition according to claim 8 , in which the lysozyme is an ...

Подробнее
Номер записи: 52
10-10-2013 дата публикации

THERAPEUTIC AGENT FOR DISC HERNIATION

Номер: US20130266555A1
Автор: Murayama Takao, Sirogane Taiichi, Yaguchi Masafumi
Принадлежит: Seikagaku Corporation

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk. 1. A therapeutic agent for disc herniation , which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.2. The therapeutic agent according to claim 1 , wherein the disc herniation is a lumbar disc herniation.3. The therapeutic agent according to claim 1 , wherein the chondroitinase ABC is derived from Proteus vulgaris.4. A formulation containing chondroitinase ABC for treating disc herniation by the administration into a human disk in an amount of 1-8 units per disk.5. The formulation according to claim 4 , wherein the formulation is a single dose formulation.6. The formulation according to claim 4 , wherein the formulation is an injection.7. The formulation according to claim 4 , wherein the disc herniation is a lumbar disc herniation.8. A method for treating disc herniation claim 4 , comprising administering chondroitinase ABC to a human disk of a patient with disc herniation in an effective amount of 1-8 units per disk.9. (canceled) The present invention relates to a therapeutic agent for disc herniation containing chondroitinase ABC as an active ingredient.Disc herniation is a disease that causes leg pain, low back pain, and the like due to the pressure on nerves of spinal cords, and the like, attributed to protrusion of the disc tissue into ...

Подробнее
Номер записи: 53
17-10-2013 дата публикации

COMPOSITION AND METHOD FOR MODULATING INFLAMMATORY MOLECULES WITH AMYLASE

Номер: US20130273026A1
Автор: Gavini Madhavi, Srinivas Raja
Принадлежит:

A method and composition for treating in a mammalian subject a condition accompanied or caused by IgE mediated histamine release from mast cells comprising administering to a subject in need of such treatment a therapeutically effective amount of the pharmaceutical composition an amylase peptide or derivative thereof. 1. A method of modulating IgE mediated histamine release from an IgE receptor-positive cell capable of releasing histamine in-vitro or in-vivo comprising:providing an effective dose of an Amylase peptide or a derivative thereof to the IgE receptor-positive cell in-vitro or in-vivo under conditions that would permit binding of Amylase to free IgE in solution to form an IgE-Amylase binding pair thereby inhibiting the binding of free IgE to the IgE receptor-positive cell.2. The method of wherein the cell is a mast cell claim 1 , a basophil or an antigen-presenting dendritic cell.3. The method of wherein the Amylase peptide is pancreatic alpha-Amylase.4. The method of wherein the Amylase peptide is selected from SEQ ID NO 1-11 or a derivative thereof.5. The method of wherein the Amylase peptide derivative is a composition having at least 90% sequence homology with amino acids 417-427 of SEQ ID NO. 1 and at least 70% sequence homology with the remaining amino acids of SEQ ID NO 1.6. A method of treating Type I diabetes claim 4 , Type II diabetes claim 4 , Obesity claim 4 , or Insulin Resistance or secondary complications associated therewith including nephropathy claim 4 , neuropathy claim 4 , retinopathy or cardiovascular disease in a mammalian subject comprising:administering to said subject a therapeutically effective amount of an alpha-Amylase peptide or a derivative thereof.7. The method of wherein the alpha-Amylase is a peptide selected from SEQ ID NO 1-11 or a derivative thereof.8. The method of wherein the Amylase peptide derivative is a composition having at least 90% sequence homology with amino acids 417-427 of SEQ ID NO. 1 and at least 70% ...

Подробнее
Номер записи: 54
24-10-2013 дата публикации

CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES

Номер: US20130281517A1
Автор: Chang Pei-Teh, Chern Ji-Wang, LAI Shin-yu
Принадлежит:

Cyclopropanecarboxylate esters of purine analogues, method of making and using the same for treating herpes virus infections and tumors are disclosed. 2. The compound of claim 1 , wherein{'sub': x', 'y, 'Rand Rare each independently hydrogen or methyl; and'}{'sub': 'y', 'Ris hydrogen, methyl, trifluoromethyl, phenyl, 4-bromophenyl, 2-furyl, or 2-pyridyl.'}3. The compound of claim 2 , wherein{'sub': x', 'z, 'Rand Rare each independently hydrogen; and'}{'sub': 'y', 'Ris hydrogen, methyl, trifluoromethyl, phenyl, 4-bromophenyl, 2-furyl, or 2-pyridyl.'}4. The compound of claim 2 , wherein{'sub': 'x', 'Ris methyl; and'}{'sub': y', 'z, 'Rand Rare each independently hydrogen.'}5. The compound of claim 2 , wherein{'sub': 'x', 'Ris hydrogen; and'}{'sub': y', 'z, 'Rand Rare each independently methyl.'}6. The compound of claim 2 , wherein the compound is selected from the group consisting of1-amino-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-yl methoxy)-3-hydroxypropyl ester,1-amino-2-(4-bromo-phenyl)-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-3-hydroxypropyl ester,1-amino-2-phenyl-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-3-hydro propyl ester,1-amino-2-methyl-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-3-hydroxypropyl ester,1-amino-2-trifluoromethyl-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-3-hydroxypropyl ester,1-amino-2-furan-2-yl-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-3-hydroxypropyl ester, and1-amino-2-pyridin-2-yl-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-yl-methoxy)-3-hydroxypropyl ester.7. The compound of claim 2 , wherein the compound is 1-methylamino-cyclopropanecarboxylic acid 2-(2-amino-6-oxo-1 claim 2 ,6-dihydro-purin-9-ylmethoxy)-3-hydroxypropyl ester.8. The compound of claim 2 , wherein the compound is 1-amino-2 claim 2 ,2-dimethyl- ...

Подробнее
Номер записи: 55
07-11-2013 дата публикации

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE

Номер: US20130295071A1
Автор: Calias Pericles, Campolieto Paul, Manning Ken, McCauley Thomas, Salamat-Miller Nazila, Shahrokh Zahra, Taylor Katherine, Zhu Gaozhong
Принадлежит:

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease. 1. A stable formulation for intrathecal administration comprising a β-Galactocerebrosidase (GLC) protein , salt , a buffering agent , a stabilizing agent and a polysorbate surfactant.2. The stable formulation of claim 1 , wherein the GLC protein is present at a concentration up to approximately 300 mg/ml.3. (canceled)4. The stable formulation of claim 1 , wherein the GLC protein comprises an amino acid sequence of SEQ ID NO:1.5. The stable formulation of claim 1 , wherein the salt is NaCl.6. The stable formulation of claim 5 , wherein the NaCl is present at a concentration ranging from approximately 0-300 mM.7. (canceled)8. The stable formulation of claim 1 , wherein the polysorbate surfactant is selected from the group consisting of polysorbate 20 claim 1 , polysorbate 40 claim 1 , polysorbate 60 claim 1 , polysorbate 80 and combinations thereof.911-. (canceled)12. The stable formulation of claim 1 , wherein the buffering agent is selected from the group consisting of phosphate claim 1 , acetate claim 1 , histidine claim 1 , sccinate claim 1 , citrate claim 1 , Tris claim 1 , and combinations thereof.12a. (canceled)13. The stable formulation of claim 60 , wherein the phosphate is present at a concentration no greater than 20 mM.14. (canceled)15. The stable formulation of claim 1 , wherein the stabilizing agent is selected from the group consisting of sucrose claim 1 , glucose claim 1 , mannitol claim 1 , sorbitol claim 1 , PEG 4000 claim 1 , histidine claim 1 , arginine claim 1 , lysine claim 1 , phospholipids and combinations thereof.1617-. (canceled)18. The stable ...

Подробнее
Номер записи: 56
21-11-2013 дата публикации

Compositions for treating microbial infections

Номер: US20130309220A1
Автор: Rueben Matalon
Принадлежит: Individual

Certain embodiments are directed to methods of treating a condition associated with microbial infection in a subject having such a condition comprising administering to the subject a composition comprising an effective amount of (a) lysozyme and (b) N-acetyl glucosamine polymer.

Подробнее
Номер записи: 57
21-11-2013 дата публикации

MATERIALS AND METHODS FOR THE PROPHYLACTIC TREATMENT OF A PRE-MALIGNANT CONDITION

Номер: US20130309249A1
Автор: Kuperwasser Charlotte, Sedic Maja
Принадлежит:

Described herein are materials and methods for the prophylactic treatment of a pre-malignant condition, comprising administering a SIRT1 agonist to an individual whose genotype comprises one defective BRCA1 allele and one functional BRCA1 allele. 1. A method for prophylactically treating an individual at risk for breast cancer or ovarian cancer , comprising identifying the individual as comprising a genotype that comprises one copy of a defective BRCA1 allele and one copy of a functional BRCA1 allele , and administering a prophylactically effective amount of a SIRT1 agonist to the individual.2. The method of claim 1 , wherein the prophylactic treatment prevents or ameliorates a pre-malignant condition associated with breast cancer or ovarian cancer.3. The method of claim 1 , wherein the SIRT1 agonist is selected from the group consisting of: a small molecule agonist claim 1 , an activating antibody and an enzymatic agonist.4. The method of claim 5 , wherein the SIRT1 agonist is selected from the group consisting of: butein claim 5 , fisetin claim 5 , isonicotinamide claim 5 , piceatannol claim 5 , quercetin and resveratrol.5. A method for prophylactically treating an individual at risk for breast cancer or ovarian cancer claim 5 , comprising identifying the individual as comprising a genotype that comprises one copy of a defective BRCA1 allele and one copy of a functional BRCA1 allele claim 5 , and administering a prophylactically effective amount of a deacetylase that deacetylates Rb.6. The method of claim 5 , further comprising administering a prophylactically effective amount of a Rb phosphorylase. This application claims the benefit of U.S. provisional application No. 61/637,578, filed Apr. 24, 2012, the entire contents of each of which are herein incorporated by reference.Individuals with inherited mutations in BRCA1 have a ˜50-85% chance of developing breast and/or ovarian cancer within their lifetimes. Although BRCA1 function appears to be essential in all ...

Подробнее
Номер записи: 58
05-12-2013 дата публикации

Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer

Номер: US20130323226A1
Автор: Bell Christie L., Vandenberghe Luc H., Wilson James M.
Принадлежит: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered. 1. A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) vector having a capsid from a clade F AAV , said method comprising delivering to a subject a composition which modifies the ability of a cell comprising a β-galactose residue to bind a clade F AAV.2. The method according to claim 1 , wherein the method comprises delivering to a subject having cells with a cell surface glycan having terminal sialic acid and a penultimate β-galactose said AAV viral vector in combination with a neuraminidase claim 1 , whereby the neuraminidase cleaves the terminal sialic acid and converts the penultimate β-galactose to a terminal β-galactose.3. The method according to claim 2 , wherein said method comprises pre-treating the subject with the neuraminidase.4. The method according to claim 2 , wherein said method comprises delivering to the subject said ...

Подробнее
Номер записи: 59
05-12-2013 дата публикации

Novel Nanoparticles of Lactoferrin Useful for Preparing a Pharmaceutical Composition Facilitating Easy Delivery of the Drug and a Process for Preparing the Same

Номер: US20130323314A1
Автор: Kondapi Anand Kumar
Принадлежит: UNIVERSITY OF HYDERABAD

Novel nanoparticles of lactoferrin useful for preparing a pharmaceutical composition facilitating easy delivery of the drug contained therein wherein the sizes are in diameter in the range of 40 to 90 nanometers. 113-. (canceled)14. Nanoparticles comprising lactoferrin and at least one additional component , wherein the lactoferrin has a diameter of 40 to 60 nanometers.15. The nanoparticles of claim 14 , wherein the at least one additional component is selected from the group consisting of antibiotics claim 14 , anti-cancer agents claim 14 , neuroactive agents claim 14 , proteins claim 14 , antibodies claim 14 , anti-HIV agents claim 14 , and DNA.16. The nanoparticles of claim 15 , wherein the antibiotic is one of cefuroxime and chloroquine.17. The nanoparticles of claim 15 , wherein the anti-cancer agent is selected from the group consisting of cyclophosphamide claim 15 , ifosfamide claim 15 , paclitaxel claim 15 , methotrexate claim 15 , fluorouracil claim 15 , doxorubicin claim 15 , daunorubicin claim 15 , cisplatin claim 15 , carboplatin claim 15 , etoposide claim 15 , cytarabine claim 15 , gemcitabine claim 15 , and docetaxel.18. The nanoparticles of claim 15 , wherein the anti-HIV agent is one of azidothymidine and enfuvirtide.19. A method of preparing lactoferrin-containing nanoparticles comprising:dissolving lactoferrin and at least one additional component in a solvent to produce a solution, wherein the solvent is selected from the group consisting of phosphate-buffered saline, Tris buffer, saline, and water;dispersing the solution in an oil at a temperature of from about 4 degrees Celsius to about 30 degrees Celsius to produce a second solution;sonicating the second solution in a sonicator in two-second pulses separated by two second periods of no pulses continuously for 15 minutes to produce a sonicated solution;freezing the sonicated solution for at least 15 minutes at below −20 degrees Celsius, followed by incubating the sonicated solution at between ...

Подробнее
Номер записи: 60
12-12-2013 дата публикации

ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCLEOSIDE HYDROLASE

Номер: US20130330315A1
Автор: PARKER William B., SORSCHER Eric J.
Принадлежит:

The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells. 110-. (canceled)11. A therapeutic comprising:a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression thereof; anda prodrug in a sustained release carrier, said prodrug cleaved by said purine nucleoside phosphorylase or nucleoside hydrolase for direct prodrug injection inhibition of replicating or non-replicating targeted cells.1220-. (canceled)21. A process of inhibiting replicating or non-replicating targeted cells comprising:delivering a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression thereof to the targeted cells; andinjecting a prodrug cleaved by said purine nucleoside phosphorylase or nucleoside hydrolase directly into proximity to the targeted cells to release a purine base cytotoxic to the targeted cells so as to inhibit the targeted cells.22. The process of wherein the targeted cells define a tumor.23. The process of wherein said purine nucleoside phosphorylase or nucleoside hydrolase is delivered with a viral vector containing a nucleic acid encoding said purine nucleoside phosphorylase or said ...

Подробнее
Номер записи: 61
19-12-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS

Номер: US20130336952A1
Автор: Braiman-Wiksman Liora, Brener Ephraim, LEVY-HACHAM Ofra, SOLOMONIK Inessa, Tennenbaum Tamar
Принадлежит: HEALOR LTD.

The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca and Mgcations. The disclosure also relates to compositions comprising an insulin or insulin analog and a pharmaceutically acceptable carrier that is free of Ca and Mg cations. 1116-. (canceled)117. A composition comprising a delta-PKC activator , an alpha-PKC inhibitor , and a pharmaceutically acceptable carrier that is free of Ca and Mg cations.118. The composition of claim 117 , wherein the delta-PKC activator is at least one selected from the group consisting of an insulin and an insulin analog.119. The composition of claim 118 , wherein the insulin analog is at least one selected from the group consisting of insulin lispro claim 118 , insulin aspart claim 118 , insulin glargine claim 118 , visfatin claim 118 , and L-α-phosphatidylinositol-3 claim 118 ,4 claim 118 ,5-trisphosphate claim 118 , dipalmitoyl- claim 118 , heptaammonium salt.120. The composition of claim 118 , wherein the insulin is at least one selected from the group consisting of human insulin claim 118 , bovine insulin claim 118 , and porcine insulin.121. The composition of claim 120 , wherein the insulin is recombinantly expressed.122. The composition of claim 118 , wherein the alpha-PKC inhibitor is a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 which has a myristoylated amino acid residue at its amino terminus.123. The composition of claim 117 , wherein the pharmaceutically acceptable carrier that is free of Caand Mg cations is an aqueous carrier comprising 0.2 g/L KCl claim 117 , 0.2 g/L anhydrous KHPO claim 117 , 8 g/L NaCl claim 117 , and 1.15 anhydrous NaHPO.124. A composition comprising an insulin ...

Подробнее
Номер записи: 62
19-12-2013 дата публикации

USE OF CREATINE KINASE FOR PREVENTING OR TREATING ADDICTION TO OPIATES

Номер: US20130336953A1
Автор: Goumon Yannick, Laux - Biehlmann Alexis, Stuber Denise
Принадлежит:

The present invention relates to creatine kinase for use as a medicinal product or in the prevention or treatment of addictions or of addictive disorders associated with opiates, and to various other analytical uses or for filtration of creatine kinase. 1) A creatine kinase or derivative thereof for prevention or treatment of an addiction or of an addictive disorder associated with opiates.2) The creatine kinase or derivative thereof as claimed in claim 1 , wherein the opiates are natural opium alkaloids.3) The creatine kinase or derivative thereof as claimed in claim 2 , wherein the natural opium alkaloids are morphine and derivatives thereof.4) The creatine kinase or derivative thereof as claimed in claim 1 , wherein the opiates are endogenous natural alkaloids claim 1 , preferably endogenous morphine and derivatives thereof.5) A creatine kinase or derivative thereof for use as a medicinal product for capturing opiates.6) A pharmaceutical composition for use in the prevention or treatment of an addiction or of an addictive disorder associated with opiates claim 1 , comprising a creatine kinase or a derivative thereof as active principle and a pharmaceutically acceptable vehicle.7) The pharmaceutical composition as claimed in claim 6 , wherein the opiates are natural opium alkaloids.8) The pharmaceutical composition as claimed in claim 7 , wherein the natural opium alkaloids are morphine and derivatives thereof.9) The pharmaceutical composition as claimed in claim 6 , wherein the opiates are endogenous natural alkaloids claim 6 , preferably endogenous morphine and derivatives thereof.10) A method of analysis of opiates in a sample comprising:a) contacting said sample with a creatine kinase or a derivative thereof;b) detecting any complexes formed between said creatine kinase or said derivative thereof and at least one opiate.11) The method of analysis as claimed in claim 10 , said method further comprising a step c) in which the results of detection obtained in ...

Подробнее
Номер записи: 63
19-12-2013 дата публикации

MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE

Номер: US20130337086A1
Автор: Goolsbee William A., Lillard Jeffrey L.
Принадлежит: BMG PHARMA LLC

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions. 1. A method for treating a mucosal disorder or a dermal disorder in a subject comprising administering to the subject a physiologically acceptable composition that comprises a mineral salt and a sulfonic acid.2. The method according to wherein the mucosal disorder comprises mucositis.3. The method according to wherein mucositis comprises inflammation of mucosa of the gastrointestinal tract claim 2 , bladder claim 2 , esophagus claim 2 , vagina claim 2 , rectum claim 2 , lung claim 2 , a nasal cavity claim 2 , an ear claim 2 , or ocular mucosa.4. The method according to wherein the mucosal disorder comprises (a) oral stomatitis claim 1 , oral mucositis claim 1 , an oral ulceration claim 1 , Crohn's disease claim 1 , periodontitis claim 1 , interstitial cystitis claim 1 , or a wound; or (b) vaginal dryness claim 1 , vaginal burning claim 1 , vaginal ulceration claim 1 , dyspareunia claim 1 , leukorrhea claim 1 , vulvar pruritus claim 1 , vulvar burning claim 1 , or atrophic vaginitis.5. (canceled)6. The method according to claim 1 , wherein the mucosal disorder is consequent to any one or more of hormone insufficiency claim 1 , bone marrow transplant claim 1 , chemotherapy claim 1 , radiation therapy claim 1 , viral infection claim 1 , fungal infection claim 1 , and bacterial infection.7. (canceled)8. (canceled)9. The method according to wherein the dermal disorder comprises diaper rash claim 1 , skin dryness claim 1 , dermatitis claim 1 , eczema claim 1 , psoriasis claim 1 , erythema claim 1 , acne claim 1 , xerosis claim 1 , and radical oxygen species-induced skin damage.10. The method according to wherein the mineral salt comprises (a) a mineral moiety selected from zinc claim 1 , calcium claim 1 , ...

Подробнее
Номер записи: 64
26-12-2013 дата публикации

ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF

Номер: US20130344145A1
Автор: Bernardo Escudero Roberto, Savoir Vilboeuf John Claude
Принадлежит: Posi Visionary Solutions LLP

A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive enzymes, a binding agent, a diluting agent, an absorbent agent, a lubricant, aglidant, and an disintegrating agent or suspending agent, effective in the normalization of intestinal disorders, to achieve an analgesic activity, to achieve an anti-spasmic activity and to reduce the symptoms associated with intestinal gas such as distention, abdominal pain and flatulence. 1. A pharmaceutical composition or formulation adapted for oral administration in tablet , coated tablet or capsule form for the prevention or treatment of intestinal disorders , the formulation is composed of: an intestinal motility modifier , an agent , which prevents the retention of gases , a digestive enzyme , a binding agent , a diluting agent , an absorbing agent , a disintegrating agent , a lubricating agent and a gliding agent.2. The pharmaceutical formulation in accordance with claim 1 , wherein the intestinal motility modifier is selected from a group which consists of: trimebutine claim 1 , fenoverine claim 1 , mebeverine claim 1 , dicycloverine claim 1 , ethyl bromide claim 1 , alosetron claim 1 , tegaserod claim 1 , loperamide claim 1 , phloroglucinol claim 1 , Trimethylphloroglucinol claim 1 , Butylscopolamine claim 1 , and pargeverine.3. The pharmaceutical formulation in accordance with claim 2 , wherein the intestinal motility modifier is trimebutine and its acceptable pharmaceutical salts.4. The pharmaceutical formulation in accordance with claim 2 , wherein the intestinal motility modifier is fenoverine and its acceptable pharmaceutical salts.5. The pharmaceutical formulation in accordance with claim 2 , wherein the intestinal ...

Подробнее
Номер записи: 65
02-01-2014 дата публикации

COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS

Номер: US20140005119A1
Автор: Chao Wang, Weiping Zheng, Yujun Hao, Zhengne Wang
Принадлежит: CASE WESTERN RESERVE UNIVERSITY

A method of inhibiting the activity, signaling, and/or function of a p110α mutant protein in a cancer cell expressing the p110α mutant protein includes administering to the cancer cell an amount of a therapeutic agent effective to inhibit binding of the p110α mutant protein to IRS1 in the cell.

Подробнее
Номер записи: 66
09-01-2014 дата публикации

HEMOGLOBIN COMPOSITIONS

Номер: US20140011741A1
Автор: ABUCHOWSKI Abraham, KAZO Friedericke, KAZO Glenn
Принадлежит:

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs. 1. A method of synergistically treating inflammation , vasoconstriction and hypoxia in a patient in need of such treatment , by administering to said patient a therapeutically effective amount of a PEGylated hemoglobin (PEG-Hb) conjugate wherein the hemoglobin has an average Pof from about 7 mm Hg to about 16 mm Hg , and wherein at least 95% of said conjugate is in the form of PEGylated carboxyhemoglobin (PEG-COHb).2. The method of wherein said treatment simultaneously disrupts the hemolytic and ischemic pathways associated with injury to tissue.3. The method of wherein the hemoglobin and carboxyhemoglobin is bovine.4. The method of claim 1 , wherein the hemoglobin has an average Pof from about 11 mm Hg to about 15 mm Hg.5. The method of wherein said conjugate comprises 8 to 10 molecules of 5000-molecular-weight PEG claim 1 , conjugated to a molecule of bovine hemoglobin claim 1 , the conjugate having a total molecular weight of about 109 KD.6. The method of wherein said conjugate is provided in a saline aqueous solution comprising ...

Подробнее
Номер записи: 67
09-01-2014 дата публикации

METHOD AND APPARATUS FOR TREATMENT OF CARDIAC DISORDERS

Номер: US20140012230A1
Автор: Keimel John G.
Принадлежит: Medtronic, Inc.

The present invention is directed to systems and methods for delivering therapy for a cardiac disorder, wherein the system comprises a source for supplying a protein formulation containing a protein that is otherwise deficient in cardiac cells in a patient with a cardiac disorder, and a catheter having a proximal end and a distal end for delivering the protein formulation to the pericardial sac region of a human heart. 1. (canceled)226-. (canceled)27. A method comprising:delivering a therapeutic protein formulation from an implantable source through an implantable catheter directly to a pericardial sac region of a heart of a patient,wherein the patient has a cardiac disorder caused by a protein deficiency due to a gene mutation,wherein the therapeutic protein formulation comprises a protein in a form that is deficient in cardiac cells of the patient due to the gene mutation, andwherein the therapeutic protein formulation is delivered at a rate based on the sequence of the patient's gene mutation.28. The method of claim 27 , wherein the protein formulation comprises at least one species operable for maintaining a desired pH.29. The method of claim 27 , wherein the implantable source comprises a refillable reservoir to store the protein formulation.30. The method of claim 27 , wherein the cardiac disorder is glycogen storage disease Type II or Fabry disease.31. The method of claim 30 , wherein the protein is lysosomal acid α-glucosidase or α-galactosidase.32. The method of claim 27 , wherein the cardiac disorder is glycogen storage disease Type II and the protein is lysosomal acid α-glucosidase.33. The method of claim 27 , wherein the cardiac disorder is Fabry disease and the protein is α-galactosidase.34. The method of claim 27 , further comprising administering an RNA interference therapy to the patient to inhibit production of a mutated protein resulting from the gene mutation.35. The method of claim 27 , wherein the rate of delivery of the therapeutic protein ...

Подробнее
Номер записи: 68
16-01-2014 дата публикации

TREATMENT OF OPHTHALMIC CONDITIONS

Номер: US20140017220A1
Автор: Sancho Alberto Osio
Принадлежит: Osio Corporation d/b/a Yolia Health

Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system. 149-. (canceled)50. A non-invasive method for treating myopia , the method comprising steps of:providing a contact lens;providing eye drops comprising an effective amount of hyaluronidase and collagenase, wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2;applying the contact lens to an eye of a patient suffering from myopia; andapplying the eye drops to the eye of the patient;wherein the treatment corrects the patient's far vision, and the treatment results in corrected vision for at least 6 months.51. A non-invasive method for treating hyperopia , the method comprising steps of:providing a contact lens;providing eye drops comprising an effective amount of hyaluronidase and collagenase, wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2;applying the contact lens to an eye of a patient suffering from hyperopia; andapplying the eye drops to the eye of the patient; ...

Подробнее
Номер записи: 69
16-01-2014 дата публикации

NOVEL ENDOLYSIN

Номер: US20140017224A1
Автор: Branco Dos Santos Silvio Roberto, Kluskens Leonardus Dorothea, Lavigne Rob, Rodrigues Azeredo Joana Cecilia Valente, Walmagh Maarten
Принадлежит:

The present invention relates to a polypeptide with endolysin activity comprising an amino acid sequence according to SEQ ID No. 1 and fragments or derivatives thereof, or fusion proteins derived thereof. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide, fragment, derivative or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide, fragment, derivative or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide, fragment, derivative or fusion protein. 1. A polypeptide having endolysin activity comprising an amino acid sequence according to SEQ ID NO: 1 or a fragment or derivative thereof.2. The polypeptide according to claim 1 , wherein the fragment comprises an amino acid sequence according to SEQ ID NO: 3 and/or 5.3. The polypeptide according to claim 1 , wherein the derivative has a deletion claim 1 , addition claim 1 , insertion and/or substitution in the amino acid sequence according to SEQ ID NO: 1 claim 1 , 3 claim 1 , and/or 5.4. The polypeptide according to claim 1 , wherein the polypeptide is fused at the N- or C-terminus to a peptide stretch having membrane or LPS disrupting activity.5. The polypeptide according to comprising additionally a tag claim 1 , preferably a His6-tag.6. The polypeptide ...

Подробнее
Номер записи: 70
23-01-2014 дата публикации

HETEROMULTIVALENT NANOPARTICLE COMPOSITIONS

Номер: US20140023591A1
Автор: Modery Christa, Ravikumar Madhumitha, Sen Gupta Anirban
Принадлежит: CASE WESTERN RESERVE UNIVERSITY

A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. 1. A composition for use in diagnostic and therapeutic applications comprising a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle , the targeting moieties including a first activated platelet targeting moiety and a second activated platelet targeting moiety , and wherein the composition is capable of binding activated platelets at a thrombus site under a hemodynamic shear environment.2. The composition of claim 1 , the nanoparticle comprising a liposome.3. The composition of claim 1 , the first activated platelet targeting moiety comprising a GPIIb-IIIa-binding peptide and the second activated platelet targeting moiety comprising a p-selectin binding peptide.4. The composition of claim 3 , the GPIIb-IIIa-binding peptide comprising a RGD small peptide and the p-selectin binding peptide comprising a EWVDV small peptide.5. The composition of claim 4 , the RGD small peptide having SEQ ID NO:3 and the p-selectin binding peptide having SEQ ID NO:1.6. The composition of claim 1 , wherein the first and second activated platelet targeting moieties are conjugated to the nanoparticle surface with PEG linkers.7. The composition of claim 1 , wherein the first and second activated platelet targeting moieties can be spatially or topographically arranged on the nanoparticle surface such that the first and second activated platelet targeting moieties do not spatially mask each other and the nanoparticle is able to bind to an activated platelet with exposed activated platelet receptors thereby enhancing retention of the nanoparticle construct onto activated ...

Подробнее
Номер записи: 71
23-01-2014 дата публикации

METHODS OF TREATING ANEMIA AND RED BLOOD CELL DYSFUNCTION WITH LECITHIN CHOLESTEROL ACYLTRANSFERASE

Номер: US20140023631A1
Автор: Auerbach Bruce J., Homan Reynold, KRAUSE Brian
Принадлежит: ALPHACORE PHARMA, LLC

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells. 154-. (canceled)55. A method of improving a condition characterized by one or more of the following: anemia , red blood cells with reduced ability to deform , reduced RBC oxygenation , increased RBC aggregation and adhesion , reduced nitric oxide function , decreased RBC life-span comprising:a) obtaining a base-line measurement of one or more than one of the following: hemoglobin level, hematocrit level, RBC deformability, RBC oxygenation, RBC aggregation and adhesion, or RBC life-span;b) administering to a patient in need thereof a therapeutically effective amount of an agent which increases the activity of LCAT or increases the plasma level of LCAT or both;c) obtaining a post-treatment measurement of one or more of the following: hemoglobin level, hematocrit level, RBC deformability, RBC oxygenation, RBC aggregation and adhesion, or RBC life-span; andd) comparing the baseline measurement with the post-treatment measurement wherein the occurrence of one or more of the following: an increase in hemoglobin level, an increase in hematocrit level, an increase in RBC deformability, an increase in RBC oxygenation, a decrease in RBC aggregation and adhesion, or an increase in RBC life-span, indicates an improvement in the condition.56. The method according to claim 55 , wherein the condition is sickle cell disease claim 55 , diabetes claim 55 , thalassemia claim 55 , rheumatoid disease ...

Подробнее
Номер записи: 72
23-01-2014 дата публикации

USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION

Номер: US20140023633A1
Автор: Forsberg Neil E., Puntenney Steven B.
Принадлежит: OmniGen Research, L.L.C.

A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. 1. A method for reducing a stress effect in an animal , comprising administering to an animal having an increased stress indicator a composition comprising β-glucans , β-1 ,3 (4)-endoglucanohydrolase , silica , a mineral clay , and mannans , wherein the animal is selected from mammalian and avian species , thereby reducing a stress effect in the animal.2. The method of where the increased stress indicator is an elevated stress hormone level and the stress effect is immunosuppression mediated by the elevated stress hormone level.3. The method of where the elevated stress hormone is cortisol claim 2 , hydrocortisone claim 2 , corticosterone claim 2 , or a combination thereof.4. The method of where the elevated stress hormone level includes elevated glucocorticoids.5. The method of where the composition is administered to the animal at or around a time of parturition.6. The method of claim 1 , further comprising administering the composition to the animal as a prophylactic to prevent colonization or growth of pathogenic fungal or bacterial species in the animal.7. The method of where administering the composition augments the animal's innate immune function.8. The method of where augmenting the animal's innate immune function includes increasing the expression of L-selectin claim 7 , interleukin-1β claim 7 , or a combination thereof.9. The method of where the silica is provided by diatomaceous earth.10. The method of where the mannans comprise glucomannan.11. The method of where the mineral clay comprises ...

Подробнее
Номер записи: 73
30-01-2014 дата публикации

EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS

Номер: US20140030244A1
Автор: Paylian Sergei
Принадлежит: BIOQUARK, INC.

The described invention provides methods for preparing a composition containing extracts of activated amphibian oocytes, the method where the composition is a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and a method for treating a disease, disorder, condition or injury characterized by a damaged or a cancerous differentiated cell including: (a) preparing the composition by the described method; (b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier; and (c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof, where the therapeutic amount is effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition. 1. A method for preparing a composition comprising extracts of activated amphibian oocytes comprising:(a) providing a suspension of oocytes harvested from an amphibian, in a buffered oocyte washing solution in an oocyte activation vessel;(b) applying an electroporation stimulus to the suspended oocytes of (a) in the oocyte activation vessel to produce a suspension of activated oocytes;(c) combining an aqueous energy solution with the suspension of activated oocytes to form an aqueous suspension;(d) incubating the aqueous suspension of (c) at an incubation temperature of 16° C. to 20° C., for an incubation time of about 2 to about 4 hours;(e) partitioning the incubated combination of (d) to obtain a portion external to the incubated activated oocytes (extra-oocyte portion), and an activated oocyte portion that includes the incubated activated oocytes of (d);(f) separating the extra-oocyte portion and the activated oocyte portion from each other;(g) filtering the extra-oocyte ...

Подробнее
Номер записи: 74
30-01-2014 дата публикации

Novel Pharmaceutical Preparation for Preeclampsia, Eclampsia, and Toxemia and Their Related Symptoms and Related Disorders of Pregnancy

Номер: US20140030333A1
Автор: Fallon Joan M.
Принадлежит: CUREMARK, LLC

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. 1. A method for treating an individual exhibiting one or more symptoms of preeclampsia , the method comprising administering a therapeutically effective amount of digestive enzymes to the individual.2. The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is selected from the group consisting of: amylase claim 1 , lipase claim 1 , protease claim 1 , and a combination thereof.3. The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is further selected from the group consisting of: chymotrypsin claim 1 , trypsin claim 1 , pancreatin claim 1 , papaya claim 1 , papain claim 1 , and a combination thereof.4. The pharmaceutical preparation of claim 1 , wherein the enzymes are derived from a source selected from the group consisting of animal enzymes claim 1 , plant enzymes claim 1 , synthetic enzymes claim 1 , and a combination thereof.5. The pharmaceutical preparation of wherein the preparation is manufactured using a technology selected from the group consisting of Proslv® technology claim 1 , enteric coating claim 1 , lipid encapsulation claim 1 , direct compression claim 1 , dry granulation claim 1 , wet granulation claim 1 , and a combination thereof.6. The pharmaceutical preparation of claim 1 , wherein the preparation is administered orally via ...

Подробнее
Номер записи: 75
06-02-2014 дата публикации

Treatment of Pompe's Disease

Номер: US20140037611A1
Автор: Meeker David P., van Bree Johannes B.M.M., Venneker Edna H.G.
Принадлежит: Genzyme Therapeutic Products Limited Partnership

The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. 1. A method of treating a patient with Pompe's disease , comprising:administering to the patient a therapeutically effective amount of human acid alpha glucosidase.2. The method of claim 1 , wherein the patient is administered at least 10 mg/kg body weight per week.3. The method of claim 1 , wherein the patient is administered at least 60 mg/kg body weight per week.4. The method of claim 1 , wherein the patient is administered at least 120 mg/kg body weight per week.57-. (canceled)8. The method of claim 1 , wherein the alpha-glucosidase is administered intravenously.10. The method of claim 1 , wherein the patient has infantile Pompe's disease.11. The method of claim 10 , wherein the patient survives to be at least one year old.12. The method of claim 1 , wherein the patient has juvenile Pompe's disease.13. The method of claim 1 , wherein the patient has adult Pompe's disease.14. The method of claim 1 , wherein the alpha-glucosidase is predominantly in a 110 kD form.15. The method of claim 1 , further comprising monitoring a level of human acid alpha glucosidase in the patient.1626-. (canceled)27. A pharmaceutical composition comprising human acid alpha .glucosidase claim 1 , human serum albumin claim 1 , and a sugar in a physiologically acceptable buffer in sterile form.28. The pharmaceutical composition of comprising human acid alpha glucosidase claim 27 , human serum albumin claim 27 , and glucose in sodium phosphate buffer.29. A pharmaceutical composition comprising alpha glucosidase claim 27 , mannitol and sucrose in an aqueous solution.30. The pharmaceutical composition of claim 27 , wherein the sugar comprises mannitol and sucrose and the concentration of mannitol is 1-3% w/w of the aqueous solution and the concentration of sucrose is 0.1 to 1% w/w of the ...

Подробнее
Номер записи: 76
06-02-2014 дата публикации

SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A

Номер: US20140037612A1
Автор: Heartlein Michael W., Lamsa Justin C., Nguyen Vinh, Shahrokh Zahra, Sturk Lisa Marie, Taylor Katherine D.
Принадлежит: Shire Human Genetic Therapies Inc.

The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. 1. A composition comprising from about 1 mg/ml to about 60 mg/ml α-Gal A , from about 2% to about 10% (w/v) carbohydrate , from about 5 mM to about 10 mM citrate , up to 3% (v/v) excipient , from about 0.05% to about 0.5% (v/v) surfactant , and having a pH of 6.0.24-. (canceled)5. A composition comprising 30 mg/ml of α-Gal A , 5% (w/v) sucrose , 5 mM citrate , between about 1% and 2.5% (v/v) glycerol , and 0.05% (v/v) poloxamer 188 , and having a pH of 6.0.6. A composition comprising from about 1 mg/ml to about 60 mg/ml α-Gal A , from about 2% to about 10% (w/v) carbohydrate , from about 5 mM to about 10 mM citrate , about 1% or less of an antimicrobial agent , up to 3% (v/v) excipient , and having a pH of 6.0.79-. (canceled)10. A composition comprising 30 mg/ml of α-Gal A , 5% (w/v) sucrose , 5 mM citrate , 1% or less (v/v) benzyl alcohol , up to 3% (v/v) glycerol , and having a pH of 6.0.11. A method of enhancing delivery of α-Gal A to the kidneys in an individual with Fabry disease , the method comprising administering human α-Gal A to the individual by an oral route or a parenteral route.12. The method of claim 11 , wherein the parenteral route is selected from the group consisting of the following routes: intra-arterial claim 11 , intraperitoneal claim 11 , ophthalmic claim 11 , intramuscular claim 11 , vaginal claim 11 , intraorbital claim 11 , intracerebral claim 11 , intradermal claim 11 , intracranial claim 11 , intraspinal claim 11 , intraventricular claim 11 , intrathecal claim 11 , intracisternal claim 11 , intracapsular claim 11 , intrapulmonary claim 11 , intranasal claim 11 , transmucosal claim 11 , transdermal and inhalation.1314-. (canceled)15. The method of claim 11 , wherein α-Gal A is administered in sufficient dose to result in kidney α-Gal A levels in the individual that result in an ...

Подробнее
Номер записи: 77
06-02-2014 дата публикации

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

Номер: US20140037613A1
Автор: Bookbinder Louis H., Frost Gregory I., Kundu Anirban
Принадлежит:

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. 1. A pharmaceutical composition , comprising:a) a soluble neutral active human hyaluronidase glycoprotein (sHASEGP); and{'i': Haemophilus Influenza', 'Hemophilus influenza', 'Bacillus, "b) a pharmacologic or pharmaceutically effective agent selected from among Adalimumabs, Agalsidase Betas, Alefacepts, Ampicillins, Anakinras, Antipoliomyelitic Vaccines, Anti-Thymocytes, Azithromycins, Becaplermins, Caspofungins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, Cetuximabs, Cilastatins, Clavulanic Acids, Clindamycins, Darbepoetin Alphas, Daclizumabs, Diphtheria, Diphtheria antitoxins, Diphtheria Toxoids, Efalizumabs, Epinephrines, Erythropoietin Alphas, Etanercepts, Filgrastims, Fluconazoles, Follicle-Stimulating Hormones, Follitropin Alphas, Follitropin Betas, Fosphenyloins, Gadodiamides, Gadopentetates, Gatifloxacins, Glatiramers, GM-CSF's, Goserelins, Goserelin acetates, Granisetrons, B's, Haloperidols, Hepatitis vaccines, Hepatitis A Vaccines, Hepatitis B Vaccines, Immunoglobulins, vaccines, Influenza Virus Vaccines, ...

Подробнее
Номер записи: 78
13-02-2014 дата публикации

PHARMACEUTICAL COMPOSITION FOR TREATING LYSOSOMAL STORAGE DISEASE

Номер: US20140044694A1
Автор: Otomo Takanobu, Ozono Keiichi, SAKAI Norio
Принадлежит: OSAKA UNVERSITY

The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease. 111.-. (canceled)12. A pharmaceutical composition for treating mucolipidosis type II or type III , comprising a group of purified lysosomal enzymes as an active ingredient , wherein the group of lysosomal enzymes is obtained by culturing a cell , and the group of purified lysosomal enzymes comprises at least α-mannosidase , α-fucosidase , α-galactosidase , α-glucosidase , β-galactosidase , β-glucosidase , β-hexosaminidase , β-glucuronidase , galactocerebrosidase , and cathepsin.13. The pharmaceutical composition according to claim 12 , wherein the cell has the ability to add a mannose 6-phosphate residue to lysosomal enzymes.14. The pharmaceutical composition according to claim 12 , wherein the cell is derived from a subject not suffering from lysosomal disease.15. The pharmaceutical composition according to claim 12 , wherein the group of lysosomal enzymes is obtained by a method comprising the following steps:adding to a cell one or more reagents selected from the group consisting of amphiphilic amines, lysosome-tropic amines, ionophores, and V-ATPase inhibitors, followed by culturing;collecting a culture supernatant; andpurifying the obtained culture supernatant.16. The pharmaceutical composition according to claim 15 , wherein the reagent(s) is selected from the group consisting of ammonium chloride claim 15 , chloroquine claim 15 , monencin claim 15 , nigericin claim 15 , and bafilomycin A1.17. The pharmaceutical composition ...

Подробнее
Номер записи: 79
20-02-2014 дата публикации

SCAVENGER RECEPTOR UPTAKE FOR FABRY DISEASE ENZYME REPLACEMENT THERAPY

Номер: US20140050666A1
Автор: Calhoun David H., Gilchrist Lane
Принадлежит: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK

The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme. 1. A composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand.2. The composition of claim 1 , wherein said lysosomal enzyme is selected from the group consisting of α-galactosidase A claim 1 , α-sialidase claim 1 , α-mannosidase claim 1 , β-mannosidase claim 1 , glycosylasparaginase claim 1 , α-fucosidase claim 1 ,α-N-acetylglucosaminidase claim 1 , β-galactosidase claim 1 , β-hexosaminidase claim 1 , α-subunit claim 1 , β-hexosaminidase β-subunit claim 1 , GM2 activator protein claim 1 , glucocerebrosidase claim 1 , saposin C claim 1 , arylsulfatase A claim 1 , saposin B claim 1 , formyl-glycin generating enzyme claim 1 , β-galactosylceramidase claim 1 , iduronate sulfatase claim 1 , α-iduronidase claim 1 , heparan N-sulfatase claim 1 , acetyl-CoA transferase claim 1 , N-acetyl glucosaminidase claim 1 , β-glucuronidase claim 1 , N-acetyl glucosamine 6-sulfatase claim 1 , N-acetylgalactosamine 4-sulfatase claim 1 , galactose 6-sulfatase claim 1 , hyaluronidase claim 1 , α-glucosidase claim 1 , acid sphingomyelinase claim 1 , acid ceramidase claim 1 , acid lipase claim 1 , cathepsin K claim 1 , cathepsin A claim 1 , tripeptidyl peptidase claim 1 , palmitoyl-protein thioesterase.3. The composition of claim 1 , wherein said ...

Подробнее
Номер записи: 80
20-02-2014 дата публикации

USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY

Номер: US20140050714A1
Автор: Jaattela Marja H., Jensen Thomas Kirkegaard
Принадлежит: ORPHAZYME APS

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP. 1. A method for treatment of a lysosomal storage disease comprising administration to an individual in need thereof a bioactive agent capable of increasing the intracellular concentration of Hsp70 by amplifying Hsp70 gene expression , wherein said bioactive agent is a hydroxylamine derivative.2. The method according to claim 1 , wherein said treatment is curative or ameliorating.3. The method according to claim 1 , wherein said treatment is administered prior to onset of the disease.4. The method according to claim 1 , wherein said bioactive agent is capable of amplifying Hsp70 gene expression with a concomitant stress.5. The method according to claim 1 , wherein said hydroxylamine derivative is bimoclomol claim 1 , or a structural analogue thereof.6. The method according to claim 1 , wherein said hydroxylamine derivative is selected from the group consisting of bimoclomol claim 1 , BRLP-42 claim 1 , arimoclomol claim 1 , BRX-220 claim 1 , BRX-345 and BGP-15.7. The method according to claim 1 , wherein said hydroxylamine derivative is arimoclomol.8. The method according to claim 1 , wherein said hydroxylamine derivative is BRX-345.9. The method according to claim 1 , wherein said lysosomal storage disease is selected from the group consisting of Niemann-Pick disease claim 1 , Farber disease claim 1 , Krabbe disease claim 1 , Fabry disease claim 1 , Gaucher disease claim 1 , Sialidosis claim 1 , Metachromatic leukodystrophy and saposin-deficiency.10. The method according to claim 9 , wherein said Niemann-Pick disease is selected from ...

Подробнее
Номер записи: 81
20-02-2014 дата публикации

PROTEIN HYDROLYSATES AS AGENTS FOR OVERCOMING ADDICTION

Номер: US20140050715A1
Автор: Fernandez-Ruemann Guillen Santiago Eusebio, Goralczyk Regina, Kloek Joris, Kroes Marijn Christoffrel Waander, Mohajeri Hasan, Van Wingen Guido Alexander, Wittwer Jonas
Принадлежит: DSM IP ASSETS B.V.

This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit. 1. Use of a hydrolyzed lysozyme composition to assist an animal , including a human , in refraining from engaging in an undesired behavior , and/or refraining from indulging in an addictive behavior and/or reward-seeking behavior.2. Use according to wherein the animal is a human.3. Use according to wherein the animal is an animal in a zoo claim 1 , a farm animal claim 1 , a pet or companion animal claim 1 , or a racing animal.4. Use according to wherein the behavior is selected from the group consisting of: smoking claim 1 , alcohol abuse claim 1 , gambling claim 1 , drug abuse claim 1 , compulsive behaviors claim 1 , uncontrollable behaviors such as compulsive shopping claim 1 , eating claim 1 , hoarding claim 1 , improper sexual behaviors claim 1 , kleptomania claim 1 , pyromania claim 1 , cutting or self harm claim 1 , cravings claim 1 , and potentially harmful risky behaviors.5. Use according to wherein the behavior is a habit which the individual wishes to break.6. Use according to wherein the hydrolyzed lysozyme composition is present in a food claim 1 , feed claim 1 , nutraceutical claim 1 , or food supplement.7. Use according to as an adjunctive treatment or supportive accompanying diet during dehabituation programs claim 1 , or to assist dehabituation processes.8. Use according to wherein the hydrolyzed lysozyme composition is characterized by: a Trp/LNAA ratio between 0.15 and 0.20.9. A method of assisting an animal claim 1 , including a human claim 1 , in refraining from an undesired behavior claim 1 , and/or resisting from indulging in an addictive behavior comprising:a) administering a hydrolyzed lysozyme composition, and b) noticing abstinence from the behavior.10. A method according to wherein the animal is a human.11. A method according to ...

Подробнее
Номер записи: 82
27-02-2014 дата публикации

Targeted therapeutic proteins

Номер: US20140056867A1
Автор: Jonathan Lebowitz, Stephen M. Beverley
Принадлежит: Biomarin Pharmaceutical Inc

Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Подробнее
Номер записи: 83
06-03-2014 дата публикации

TREATMENT FOR IgE-MEDIATED DISEASE

Номер: US20140065128A1
Автор: Allhorn Maria, Carlstrom Karl, Collin Mattias, Lood Rolf, Nimmerjahn Falk, Sjogren Jonathan
Принадлежит: HANSA MEDICAL AB

The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies. 19-. (canceled)10. A method of treating a disease or condition mediated by IgE antibodies in a subject , the method comprising administering to the subject a therapeutically effective amount of an EndoS polypeptide , or a polynucleotide encoding an EndoS polypeptide.11. A method of treating , ex vivo , blood taken from a patient suffering from a disease or condition mediated by IgE antibodies , comprising contacting the blood with an EndoS polypeptide.12. The method of claim 11 , wherein the blood is returned to the patient after the step of contacting.13. A method of screening for a test polypeptide having one or more effects selected from:{'sub': 'D', '(i) greater affinity (lower K) for IgE compared to the affinity for IgE of an EndoS polypeptide that consists of the amino acid sequence set forth in SEQ ID NO:1,'}(ii) greater IgE endoglycosidase activity compared to the IgE endoglycosidase activity of an EndoS polypeptide that consists of the amino acid sequence set forth in SEQ ID NO:1,(iii) greater ability to remove IgE from at least one of a basophil surface and a mast cell surface compared to the IgE-removing ability of an EndoS polypeptide that consists of the amino acid sequence set forth in SEQ ID NO:1, and(iv) greater ability to reduce activity of IgE in vivo compared to in vivo IgE activity-reducing ability of an EndoS polypeptide that consists of the amino acid sequence set forth in SEQ ID NO:1,said method comprising:(a) assessing the test polypeptide for one or more of the effects of (i) to (iv) to obtain one or more test polypeptide results; and(b) comparing the one or more test polypeptide results obtained in step (a) to results obtained when assessing the EndoS polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, and thereby screening for said ...

Подробнее
Номер записи: 84
06-03-2014 дата публикации

TREATMENT METHOD FOR MICROBIAL INFECTION

Номер: US20140065161A1
Автор: Bragger Judith Mary
Принадлежит: DEC INTERNATIONAL NZ LIMITED

A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance. 152.-. (canceled)53. A method of treating or preventing a microbial infection caused by a gram-positive bacteria or a gram-negative bacteria using a formulation , a. a component or components with an isoelectric point of or greater than 6.8;', 'b. chitinase-like protein (CLP-1); and', 'c. at least one additional compound selected from the group consisting of lactoperoxidase, quiescin, jacalin-like protein, angiogenin, lactoferrin and combinations thereof;, 'the formulation including a therapeutically effective amount of a cationic fraction isolated from whole milk, processed milk or whey, wherein the cationic fraction includesthe method characterised by administering to an animal in need thereof to treat or prevent a microbial infection.54Streptococcus uberis, Staphylococcus aureusEscherichia coli.. The method of claim 53 , wherein the microbial infection is caused by at least one of or55. The method as claimed in for the treatment or prevention of bovine mastitis.56. The method of claim 53 , wherein the method is used for treating or preventing mastitis in a cow during a drying off or a dry period.57. The method of claim 53 , wherein the method is used for treating or preventing mastitis in a cow during a lactation period.58. The method of wherein the method includes applying the formulation onto or into at least one bovine teat.59. The method of claim 53 , wherein the cationic fraction includes lactoperoxidase and lactoferrin.60. The method of claim 53 , wherein the cationic fraction includes CLP-1 claim 53 , lactoperoxidase claim 53 , quiescin claim 53 , jacalin-like protein claim 53 , angiogenin claim 53 , and lactoferrin.61. The method of claim 53 , wherein the formulation includes angiogenin.62 ...

Подробнее
Номер записи: 85
13-03-2014 дата публикации

STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA

Номер: US20140072549A1
Автор: EULER Chad, FISCHETTI Vincent A., Gilmer Daniel, Schmitz Jonathan
Принадлежит:

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including and , and related conditions. The invention provides compositions and methods incorporating and utilizing derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided. 1. A pharmaceutical composition for killing gram-positive bacteria comprising the isolated lysin polypeptide comprising the amino acid sequence of SEQ ID NO:3 or variants thereof having at least 80% identity to the polypeptide of SEQ ID NO:3 and effective to kill the gram-positive bacteria.2. The composition of further comprising an effective amount of the isolated lysin polypeptide comprising the amino acid sequence of SEQ ID NO:1 claim 1 , the isolated lysin polypeptide comprising the amino acid sequence of SEQ ID NO:2 claim 1 , or variants thereof having at least 80% identity to the polypeptide of SEQ ID NO:1 or of SEQ ID NO:2 and effective to kill the gram-positive bacteria.3. (canceled)4. A pharmaceutical composition comprising a truncated lysin having the amino acid sequence of SEQ ID NO: 1 with a modification whereby the truncated lysin comprises only one catalytic domain selected from the group consisting of an endopeptidase domain and a glucosaminidase domain.5. The composition of wherein the truncated lysin does not include the glucosaminidase domain of SEQ ID NO:1.6. The composition of wherein the truncated lysin has the amino acid sequence of SEQ ID NO:2 claim 4 , or variants thereof having at least 80% identity to the polypeptide of SEQ ID NO:2 and effective to kill gram-positive bacteria.7Staphylococcus, StreptococcusListeria. An article of manufacture comprising a vessel containing the composition of and instructions for use of the composition in treatment of a patient exposed to or ...

Подробнее
Номер записи: 86
13-03-2014 дата публикации

COMPOSITION AND METHOD TO IMPROVE INTESTINAL HEALTH

Номер: US20140072621A1
Автор: de la MOTTE Carol, KESSLER Sean
Принадлежит: THE CLEVELAND CLINIC FOUNDATION

Compositions and methods are provided for treating patients suffering from compromised intestinal function, including inflammatory bowel disease. The method comprises orally administering a composition comprising hyaluronan, where said hyaluronan has a molecular weight within the range of about 35 kDa. 1. A composition comprisinghyaluronan fragments having a molecular weight of about 35 kDa; anda pharmaceutically acceptable carrier suitable for oral administration, with the proviso that said composition is substantially free of hyaluronan fragments having a molecular weight of less than 10 kDa.2. The composition of wherein the composition comprises hyaluronan fragments having a molecular weight within the range of about 15 kDa to about 75 kDa.3. The composition of wherein the composition comprises hyaluronan fragments having a molecular weight of about 25 to about 50 kDa.4. The composition of wherein the composition is substantially free of hyaluronan fragments having a molecular weight of about 4.7 kDa.5. The composition of further comprising lactoferrin.6. The composition of wherein the lactoferrin and hyaluronan are present in a 1:1 molar ratio.7. The composition of wherein the lactoferrin is conjugated to hyaluronan.8. The composition of claim 7 , wherein the composition further comprises liposomes wherein said lactoferrin and hyaluronan are linked to said liposomes.9. The composition of wherein said composition further comprises a probiotic.10. The composition of wherein said composition further comprises a standard infant formula.11. A method of treating patients in need of improved intestinal function claim 7 , said method comprising the steps ofidentifying patients suffering from compromised intestinal function; and{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'orally administering a composition of .'}12. The method of where in the patient is suffering from an inflammatory bowel disease.13. The method of where in the patient is suffering from Crohn's ...

Подробнее
Номер записи: 87
20-03-2014 дата публикации

Antibacterial Phage, Phage Peptides And Methods Of Use Thereof

Номер: US20140079671A1
Автор: da Costa Garcia Miguel Ângelo, Marçal Da Silva Filipa Maria Rodrigues Pardal Dias Antunes, Martins Barbosa Ana Raquel, Rodrigues Leandro Clara Isabel, SOUSA DE SÃO JOSÉ Carlos Jorge
Принадлежит:

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies. 1. An isolated bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO: 1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO.560 , SEQ ID NO:781 , or SEQ ID NO: 1074.216-. (canceled)17Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosaStaphylococcus aureus. An isolated protein from bacteriophage F387/08 , F391/08 , F394/08 , F488/08 , F510/08 , F44/10 , or 125/10 , or a fragment , variant or derivative thereof having antibacterial or antimicrobial activity against one or more of , and or having a biological activity associated with the bacteriophage from which it was isolated , wherein said protein is a lysin protein or a tail protein.18. (canceled)19. An isolated first protein having at least 85% or at least 95% sequence identity to a second protein of the same size ,{'i': Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa', 'Staphylococcus aureus, 'wherein said first protein has antibacterial or antimicrobial activity against , and/or and said second protein has the amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 80, SEQ ID NO: 192, SEQ ID NO: 282, SEQ ID NO: 547, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 598, SEQ ID NO: 1216, or SEQ ID NO: 1261, or a fragment thereof: or'}wherein said first protein has a biological activity associated with bacteriophage F387/08, F391/08, F394/ ...

Подробнее
Номер записи: 88
20-03-2014 дата публикации

NEW ENDOLYSIN PLYP40

Номер: US20140079727A1
Автор: Loessner Martin, Schmelcher Mathias
Принадлежит:

The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides. In addition, the present invention relates to the use of the polypeptide as a human medical, veterinary medical or diagnostic substance, as an antimicrobial substance in food, in cosmetics, as disinfecting agent or in the environmental field. 1. A polypeptide comprising an amino acid sequence according to SEQ ID NO:1 or a variant thereof.2. The polypeptide according to claim 1 , wherein the variant has a deletion claim 1 , addition claim 1 , insertion and/or substitution in the amino acid sequence according to SEQ ID NO:1.3. A nucleic acid molecule comprising a nucleotide sequence coding a polypeptide according to .4. A vector comprising a nucleic acid molecule according to .5. A host cell comprising a nucleic acid molecule according to .6listerialisteria. A method for the detection of contamination in a food comprising (a) contacting a polypeptide comprising an amino acid sequence according to SEQ ID NO:1 or a variant thereof with said food; and (b) detecting binding of said polypeptide to in said food.7. The method according to claim 6 , wherein the food comprises a dairy product claim 6 , a smoked fish claim 6 , a salted fish claim 6 , frozen seafood claim 6 , a meat product claim 6 , a salad or a convenience product.8listeria. A method for therapy and/or prevention of disease caused by comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence according to SEQ ID NO:1 or a variant thereof.9listeria. The method according to claim 8 , wherein the disease caused by comprises listeriosis claim 8 , gastroenteritis claim 8 , meningitis claim 8 , encephalitis claim 8 , sepsis claim 8 , local wound ...

Подробнее
Номер записи: 89
20-03-2014 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Номер: US20140079772A1
Автор: Ko Young Hee
Принадлежит:

The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I 2. The anti-cancer composition of claim 1 , wherein the hexokinase inhibitor inhibits binding of hexokinase 1 and/or hexokinase 2 to VDAC.3. The anti-cancer composition of claim 1 , wherein the hexokinase inhibitor is an amino acid sequence selected from the group consisting of: SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 8 claim 1 , SEQ ID NO: 9 claim 1 , and SEQ ID NO. 10.4. The anti-cancer composition of claim 1 , further comprising at least one additive selected from the group consisting of: phospholipids; liposomes; nanoparticles; immune system modulators and/or immune system boosters including brown rice extract claim 1 , muramyl dipeptide including analogues claim 1 , mushroom extract claim 1 , bioflavonoids claim 1 , Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) claim 1 , inhibitors of nagalase claim 1 , threonine attached to N-acetylgalactosamine claim 1 , and antibodies against nagalase; L-lactate dehydrogenase; D-lactate dehydrogenase; nicotinamide adenine dinucleotides; inhibitors for DNA replication; inhibitors for DNA binding; inhibitors for DNA transcription; inhibitors for cell cycle claim 1 , growth and/or proliferation; inhibitors for signal transduction pathways; inhibitors for angiogensis; small RNAs that interfere with normal gene control including antisense RNA claim 1 , micro RNA claim 1 , small hairpin RNA claim 1 , short hairpin RNA claim 1 , small interfering RNA; vitamin C; nutritional supplements including vitamins claim 1 , CoQ10 claim 1 , flavonoids claim 1 , free fatty acid claim 1 , alpha lipoic acid claim 1 , acai claim 1 , gogi claim 1 , mango claim 1 , pomergrante claim 1 , L-carnitine claim 1 , selenium; a less biologically active amino acid as compared to its isomer; and mixtures thereof.5. ...

Подробнее
Номер записи: 90
03-04-2014 дата публикации

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS AND ITS APPLICATIONS

Номер: US20140093486A1
Автор: CHIEN YUEH, CHIOU GUANG-YUH, Chiou Shih-Hwa, Yang Yi-Ping
Принадлежит: Taipei Veterans General Hospital

The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing three genes, Oct3/4, Sox2, and Parp1, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a method of rejuvenating cells by use of a PARylated protein or an enzyme with PARylation activity. Further provided is a method for inducing the secretion of interferon-γ inducible protein-10 (IP-10) comprising administering to a subject in need thereof an effective amount of iPSCs or iPSC-CM. 1. A method for preparing induced pluripotent stem cells (iPSCs) from somatic cells , comprising:(a) transfecting isolated somatic cells to express Oct3/4, Sox2, and Parp1; and(b) culturing the transfected somatic cells as obtained in step (a) under appropriate conditions, thereby converting the somatic cells into iPSCs and maintaining pluripotency and self-renewal ability.2. A method for preparing induced pluripotent stem cell (iPSCs) from somatic cells , comprising:(a) contacting or exposing isolated somatic cells with/to Oct3/4, Sox2, and Parp1; and(b) culturing the somatic cells as obtained in step (a) under appropriate conditions, thereby converting, at least a subset of, the population of somatic cells into iPSCs and maintaining pluripotency and self-renewal ability.3. The method of claim 1 , wherein the method does not comprise a step of transfecting claim 1 , contacting claim 1 , or exposing the somatic cells with/to c-Myc claim 1 , Klf4 claim 1 , Nanog claim 1 , Lin28 claim 1 , or any combination thereof.4. The method of claim 2 , wherein the method does not comprise a step of transfecting claim 2 , contacting claim 2 , or exposing the somatic cells with/to c-Myc claim 2 , Klf4 claim 2 , Nanog claim 2 , Lin28 claim 2 , or any combination thereof.5. The method of claim 1 , wherein the isolated somatic cells are transfected with one or more plasmid or viral vectors comprising Oct3/4 claim 1 , ...

Подробнее
Номер записи: 91
10-04-2014 дата публикации

Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture

Номер: US20140099380A1
Автор: Li Tiejun, Malakhov Michael P.
Принадлежит:

Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions. 1. A method of making a composition comprising microparticles comprising DAS181 , the method comprising:a) providing a feedstock composition comprising DAS181, a counterion and an organic solvent; andb) cooling the composition to below 25° C., whereby a composition comprising microparticles comprising DAS181 is formed.2. The method of wherein the DAS181 comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:1.3. The method of wherein the DAS181 comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:2.413.-. (canceled)14. The method of wherein the step of providing a feedstock composition containing DAS181 claim 1 , a counterion and an organic solvent at a temperature at or above about 25° C. comprises providing a solution containing DAS181 and a counterion in an aqueous solvent and adding an organic solvent to the solution containing DAS181 and a counterion in an aqueous solvent.15. The method of claim 1 , further comprising isolating the microparticles from the composition comprising microparticles claim 1 , whereby a dry powder formulation of microparticles is formed.16. (canceled)17. The method of claim 1 , wherein the feedstock composition comprises two or more counterions.1836.-. (canceled)37. The method of any of the forgoing claims claim 1 , further comprising adding a scavenging agent to the mixture comprising the active agent claim 1 , the counterion and the organic solvent or to the solution comprising the active agent and the counterion.38. The method of claim 37 , wherein the scavenging agent is selected from among an amine claim 37 , an antioxidant claim 37 , a sugar claim 37 , a ...

Подробнее
Номер записи: 92
10-04-2014 дата публикации

Gene Delivery Vehicles in the Treatment of Neurodegenerative Diseases

Номер: US20140100265A1
Автор: Burke Robert E.
Принадлежит: The Trustees of Columbia University in the City of New York

Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as Parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed. An alternative approach such as viral construct transduction may be used to directly activate the intracellular signaling pathways that mediate neurotrophic effects and induce axon growth. Viral construct transduction of dopaminergic neurons with a constitutively active human form of the p70S6K gene—hp70S6K (CA)—was shown to induce axon regeneration from living dopaminergic cell bodies that had no living axons. 1. A method comprising:(a) identifying a subject that has or is at risk of developing Parkinson's disease;(b) contacting neurons in the substantia nigra in the subject with a therapeutically effective amount of a gene delivery vehicle comprising a gene hp70S6K(CA) identified by SEQ ID NO. 1 that encodes a constitutively active form of protein hp70S6K (delC/T389E) identified by SEQ ID NO. 2 or a biologically active form or variant thereof, in an amount that promotes axon regeneration in dopaminergic neurons of the substantia nigra, wherein the gene delivery vehicle is administered under conditions that permit transduction of the neurons with the gene delivery vehicle thereby treating the subject.2. The method of claim 1 , wherein the substantia nigra neurons are contacted with the gene delivery vehicle by stereotaxic microinjection of the viral construct into the substantia nigra.3. The method of claim 1 , wherein the subject is human.4. The method of wherein the gene delivery vehicle is a viral construct.5. The method of claim 4 , wherein the viral construct is an adeno-associated construct that comprises a serotype selected from the group consisting of AAV-1 claim 4 , AAV-2 claim 4 , AAV-3 claim 4 , AAV-4 claim 4 , AAV-5 claim 4 , AAV-6 claim 4 , AAV-9 claim 4 , AAV-10 claim 4 , and AAV-11.6. The ...

Подробнее
Номер записи: 93
06-01-2022 дата публикации

ANTI-PATHOGENIC ACTIVITY OF A BIFUNCTIONAL PEPTIDOGLYCAN/CHITIN HYDROLASE

Номер: US20220000122A1
Автор: Allonsius Camille, LEBEER Sarah
Принадлежит:

The present invention generally relates to the use of a bifunctional peptidoglycan/chitin hydrolase to reduce and/or prevent hyphae formation in a pathogen, and/or to reduce or prevent biofilm formation. The present invention further relates to a bifunctional peptidoglycan/chitin hydrolase for use in the treatment and/or prevention of pathogenic infections, in particular yeast or bacterial infections. In another aspect, the present invention provides the use of a bifunctional peptidoglycan/chitin hydrolase as a anti-pathogenic agent in non-medical applications; in particular in the personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol and crop protection industry. 122-. (canceled)23. A method of reducing and/or preventing hyphae formation in a pathogen , the method comprising contacting the pathogen with a bifunctional peptidoglycan/chitin hydrolase.24. The method according to claim 23 , wherein the bifunctional peptidoglycan/chitin hydrolase is present in a composition.25. The method according to claim 23 , wherein the bifunctional peptidoglycan/chitin hydrolase is major secreted protein 1 (Msp1).26. The method according to claim 23 , wherein the bifunctional peptidoglycan/chitin hydrolase comprises at least 70% sequence homology to SEQ ID NO: 1.27. The method according to claim 23 , wherein the bifunctional peptidoglycan/chitin hydrolase comprises at least 70% sequence homology to SEQ ID NO: 3.28LactobacillusLactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracaseiLactobacillus fermentum.. The method according to claim 23 , wherein the bifunctional peptidoglycan/chitin hydrolase is obtained from a strain selected from the group consisting of claim 23 , and29. The method according to claim 23 , wherein the pathogen is selected from a yeast or a bacterium.30. The method according to claim 24 , wherein the composition has a pH lower than 7.31. The method according to claim 24 , wherein the composition further ...

Подробнее
Номер записи: 94
04-01-2018 дата публикации

Polypeptides Having N-Acetyl Glucosamine Oxidase Activity

Номер: US20180000076A1
Автор: Cohn Marianne Thorup, Oestergaard Lars Henrik, Schnorr Kirk Matthew
Принадлежит: NOVOZYMES A/S

The present invention relates to polypeptides having N-acetyl glucosamine oxidase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. 115-. (canceled)16. A polypeptide having N-acetyl-D-glucosamine oxidase activity , selected from the group consisting of:(a) a polypeptide having at least 75% sequence identity to the mature polypeptide of SEQ ID NO: 2;(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);(c) a polypeptide encoded by a polynucleotide having at least 75% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1 or the cDNA sequence thereof; and(d) a fragment of the polypeptide of (a), (b), or (c) that has N-acetyl-D-glucosamine oxidase activity.17. The polypeptide of claim 16 , comprising or consisting of SEQ ID NO: 2 or the mature polypeptide of SEQ ID NO: 2.18. The polypeptide of claim 16 , wherein the mature polypeptide is amino acids 20 to 632 of SEQ ID NO: 2.19. The polypeptide of claim 16 , which has at least 20% of the antimicrobial activity of the mature polypeptide of SEQ ID NO: 2.20. The polypeptide of claim 19 , wherein the antimicrobial activity is assessed using a method described in Example 6 claim 19 , 7 claim 19 , 8 claim 19 , or 9.21Aspergillus carbonariusAspergillus niger. The polypeptide of claim 19 , wherein the antimicrobial activity is assessed as fungicidal or sporicidal effect towards any of the fungal strains BR00732 (CBS 139193) and strain BR00883 (accession number CBS 139194).22. A cleaning composition consisting of the polypeptide of and one or more ingredients used in cleaning compositions claim 16 , such as a surfactant.22. A method of cleaning and/ ...

Подробнее
Номер записи: 95
05-01-2017 дата публикации

Compositions and Methods for Improved Encapsulation of Functional Proteins in Polymeric Vesicles

Номер: US20170000734A1
Автор: Ghoroghchian P. Peter, Yewle Jivan Namdeo
Принадлежит:

Methods of preparing polymersome-encapsulated functional protein suspensions may include thermally blending an amount of a block copolymer with an amount of a low molecular weight polyethylene glycol (PEG) for at least 30 minutes, mixing and cooling a resulting PEG/polymer formulation to room temperature, adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, and performing at least three dilution steps in which polymersomes that are generated are progressively saturated with the functional protein. The aliquot of the solution of the functional protein added may have a to the PEG/polymer sample of around 0.5:1 to 1.5:1 by volume, and the thermal blending may be performed at 90-100° C. 1. A method of preparing a suspension of a polymersome-encapsulated functional protein , comprising:thermally blending a quantity of a block copolymer with a quantity of a low molecular weight polyethylene glycol (PEG) for at least 30 minutes, wherein the thermal blending is performed at 90-100° C.;mixing and cooling a resulting PEG/polymer formulation to room temperature;adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, wherein a ratio of the added aliquot to the PEG/polymer formulation is between around 0.5:1 and around 1.5:1 by volume; and adding to the sample an additional amount of the solution of the functional protein;', 'mixing a resulting dispersion of the functional protein in the PEG/polymer formulation; and', 'sonicating the resulting dispersion for at least 30 minutes., 'performing at least three dilution steps such that polymersomes that are generated are progressively saturated with the functional protein, wherein each dilution step comprises2. The method of claim 1 , wherein performing the at least three dilution steps comprises performing a first claim 1 , a second claim 1 , and a third dilution step in a serial fashion claim 1 , wherein:adding the ...

Подробнее
Номер записи: 96
07-01-2016 дата публикации

Compositions and methods for treating mpsi

Номер: US20160000887A1
Автор: Brittney L. Gurda, James M. Wilson
Принадлежит: University of Pennsylvania Penn

A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes.

Подробнее
Номер записи: 97
04-01-2018 дата публикации

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC CONDITIONS

Номер: US20180000892A1
Автор: BERDEAUX Alain, GALAUP Ariane, GERMAIN Stéphane, GHALEH-MARZBAN Bijan, MONNOT Catherine, TISSIER Renaud
Принадлежит:

The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1. 1. A method of treating an ischemic condition in a subject in need thereof comprising administering to the subject a polypeptide comprising an amino acid sequence having at least 70% of identity with an amino acid sequence ranging from an amino acid residue at position 186 to an amino acid residue at position 406 in SEQ ID NO:1 , provided that said polypeptide is not SEQ ID NO:12. The method of wherein the ischemic condition is selected from the group consisting of renal ischemia claim 1 , retinal ischemia claim 1 , brain ischemia and myocardial ischemia.3. The method of wherein the ischemic condition is selected from the group consisting of coronary artery bypass graft surgery claim 1 , global cerebral ischemia due to cardiac arrest claim 1 , focal cerebral infarction claim 1 , cerebral hemorrhage claim 1 , hemorrhage infarction claim 1 , hypertensive hemorrhage claim 1 , hemorrhage due to rupture of intracranial vascular abnormalities claim 1 , subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms claim 1 , hypertensive encephalopathy claim 1 , carotid stenosis or occlusion leading to cerebral ischemia claim 1 , cardiogenic thromboembolism claim 1 , stroke claim 1 , spinal stroke and spinal cord injury claim 1 , vasculitis claim 1 , macular degeneration claim 1 , myocardial infarction claim 1 , cardiac ischemia and superaventicular tachyarrhytmia.4. The method of wherein the polypeptide is administered sequentially or concomitantly with a standard method ...

Подробнее
Номер записи: 98
03-01-2019 дата публикации

METHODS FOR TREATING CARDIAC CONDITIONS

Номер: US20190000890A1
Автор: Burrows, III Hubbard Frank, Koob Thomas J.
Принадлежит: MiMedx Group, Inc.

Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro. 1. A composition n comprising placental tissue configured for non-obstructive placement to an area approximate to a damaged cardiac tissue in an amount sufficient to reduce damage and induce healing.2. The composition of claim 1 , wherein the modified placental tissue retains an effective amount of stem cell recruiting factors claim 1 , growth factors claim 1 , and/or angiogenesis inducing factors.3. The composition of claim 1 , wherein the modified placental tissue comprises one or more of PDGF-AA claim 1 , PDGF-BB claim 1 , TGFa claim 1 , TGFB claim 1 , bFGF claim 1 , EGF claim 1 , VEGF claim 1 , IL-10 claim 1 , IL-4 claim 1 , P1GF claim 1 , TIMP-1 claim 1 , TIMP-2 claim 1 , and TIMP-4.4. The composition of any one of - claim 1 , which is a patch.5. The composition of any one of - claim 1 , wherein the modified placental tissue is micronized.6. The composition of any one of - claim 1 , which is in an injectable form.7. A method for treating injured or diseased cardiac tissue claim 1 , which method comprises placing an effective amount of a modified placenta tissue or an extract of a placental tissue at or adjacent to the injured or diseased cardiac tissue without obstructing the function thereof claim 1 , wherein the modified placenta tissue or extract is placed under conditions that promote treatment of the disease or healing of the injured or diseased cardiac tissue.8. The method of claim 7 , wherein the injured or diseased cardiac tissue is a result of ischemia claim 7 , acute myocardial infarction claim 7 , myocardial infarction claim 7 , cardiomyopathy claim 7 , unstable angina claim 7 , refractory angina claim 7 , heart attack claim 7 , heart failure claim 7 , corpulmonale claim 7 , vein graft diseases claim 7 , coronary heart diseases ...

Подробнее
Номер записи: 99
05-01-2017 дата публикации

COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION

Номер: US20170000858A1
Автор: Baumhof Patrick, Fotin-Mleczek Mariola
Принадлежит: CureVac AG

The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg);(Lys);(His);(Orn);(Xaa)with the majority of residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein. 1. An isolated mRNA comprising a polypeptide coding sequence at least 80% identical to the sequence of SEQ ID NO: 45 , wherein the sequence encodes the human UGT1A1 polypeptide.2. The isolated mRNA of claim 1 , wherein the polypeptide coding sequence is at least 85% identical to the sequence of SEQ ID NO: 45.3. The isolated mRNA of claim 2 , wherein the polypeptide coding sequence is at least 90% identical to the sequence of SEQ ID NO: 45.4. The isolated mRNA of claim 3 , wherein the polypeptide coding sequence is at least 95% identical to the sequence of SEQ ID NO: 45.5. The isolated mRNA of claim 4 , wherein the polypeptide coding sequence comprises the sequence of SEQ ID NO: 45.6. The isolated mRNA of claim 1 , wherein the mRNA is complexed with lipid.7. The isolated mRNA of claim 1 , wherein the mRNA is complexed with at least one polycationic agent.8. The isolated mRNA of claim 7 , wherein the polycationic agent is chosen from the group consisting of a polycationic lipid claim 7 , protamine claim 7 , poly-L-lysine claim 7 , poly-L-arginine and histones.9. The isolated mRNA of claim 8 , wherein the mRNA is complexed with protamine.10. The isolated mRNA of claim 1 , wherein the mRNA comprises a ...

Подробнее
Номер записи: 100